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Abstract 
 
Contemporary pacemakers allow quantification of atrial high-rate episodes (AHREs) 
and atrial fibrillation burden (AFB) accurately. Adverse left atrial (LA) remodelling is 
implicated in atrial arrhythmia. It is generally believed that LA remodelling may 
precede the development of atrial arrhythmias, and AHRE precede the clinical 
manifestation of atrial flutter or fibrillation. However, the relationship between elevated 
left ventricular filling pressure with AHRE as determined on pacemaker interrogation 
has not been studied. Furthermore, the relationship of AFB to progressive LA 
remodelling and how this in turn relates to indices of thrombogenesis is unclear. The 
aim of my study is to investigate the inter-relationship between left atrial remodelling, 
atrial arrhythmia burden and indices of thrombogenesis in patients with dual chamber 
pacemakers. My findings suggest that the incidence of AHRE was 35% in patients 
without prior diagnosis of atrial fibrillation. Increased frequency of right ventricular 
pacing is associated with left atrial enlargement and reduced global left and right 
ventricular function. However, there was no clear association between the percentages 
of right atrial pacing with cardiac remodelling. The cumulative percentage right 
ventricular pacing and increased left atrial volume are associated with the development 
of atrial high rate episodes, but atrial fibrillation burden is independently associated 
with changes in left atrial function, left ventricular diastolic function and indices of 
platelet activation and thrombosis. In addition, I demonstrated the feasibility and 
reproducibility of a novel method of IACT measurement in patients with permanent 
pacemakers. 
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CHAPTER 1. INTRODUCTION 
 
1.1 Atrial fibrillation and thromboembolism 
  
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. Its prevalence 
increases from <1% in patients <60 years old to approximately 10% in patients aged 
>80 years [Go et al. 2001]. Multiple studies assessing the secular trends of AF showed 
its increasing prevalence and incidence over the last two decades. The incidence is 
estimated to rise to about 12 million patients by 2050 in the US [Miyasaka et al. 2006]. 
Population studies suggest the lifetime risk of developing AF of approximately one in 
four men and women aged ≥ 40 years [Lloyd-Jones et al. 2004, Heeringa et al. 2006]. 
This alarming rise in AF patients may be related to the growing elderly population in 
western countries, improvements in the treatment of cardiovascular disease and 
improved detection of arrhythmia [Wattigneyet al.2003]. AF and its associated 
complications account for more than 1% of the United Kingdom health care costs 
[Stewart et al. 2001, 2004], an economic burden which has also been reported in other 
countries [Le Heuzey et al. 2004].  
 
AF is associated with increase in mortality and morbidity from thromboembolic events 
including stroke, heart failure and impaired quality of life. Patients with AF are 
estimated to have a four to five-fold increase in the risk of stroke and approximately 
15% of all strokes may be related to this arrhythmia [Wolf et al. 1991]. Patients with 
stroke associated with AF have greater disability and longer in-patient stays [Steger et 
al. 2004]. 
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The risk of systemic thromboembolism in patients with AF is related to a number of 
echocardiographic (dilated left atrium, left ventricular hypertrophy or systolic 
dysfunction or valvular heart disease) and clinical risk factors (advancing age, 
hypertension, diabetes, previous stroke or transient ischemic attack, coronary or 
peripheral vascular disease) [Stroke risk in atrial fibrillation working group 2007]. It is 
intuitively attractive to associate greater frequency and duration of AF (so-called AF 
burden) with increased risk of systemic thromboembolism. However, AF burden has 
been difficult to quantify with simple short-term non-invasive monitoring, as episodes 
of AF are often asymptomatic [Cheung et al. 2006]. Improvement in implantable device 
(pacemakers and defibrillators) technology now allows greater quantification of AF 
burden. Early data support the association between AF burden and the risk of 
thromboembolism [Watson et al. 2010]. 
 
 
1.2 Pathophysiology of prothrombotic state in AF 
 
Atrial fibrillation is believed to confer a prothrombotic and hypercoagulable state by 
fulfilling all the components of Virchow’s triad (abnormal stasis, abnormal blood 
constituents and blood vessel wall abnormalities) [Watson et al. 2009].  
 
Firstly, abnormal stasis in AF may be consequence of the loss of effective atrial 
function and progressive abnormal left atrial (LA) remodelling with dilatation. Left 
atrial size corrected to body surface area is an independent predictor of stroke [Vaziri et 
al. 1994]. Concomitant structural and valvular heart disease appears to amplify the 
adverse LA changes thereby promoting further stasis of blood. Secondly, AF is 
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associated with both macroscopic and microscopic changes in the left atria (eg: 
increased expression of vWf), which provides an ‘abnormal vessel wall’ and promotes 
thrombogenesis. Thirdly, changes in platelet, thrombotic and fibrinolytic function have 
all been demonstrated in AF patients [Choudhury and Lip 2004]. These ‘abnormal 
blood constituents’ may contribute to thrombogenesis in AF [Becker 2005]. 
 
1.3 Echocardiographic Left Atrial remodelling and development of Atrial 
Fibrillation 
 
The left atrium (LA) is structurally and functionally linked to left ventricular (LV) 
function. Functionally, the LA has been described as a reservoir during LV systole, a 
conduit during early diastole and actively contract during late diastole to aid ventricular 
filling. Hence, the LA is estimated to contribute about 15 to 30% of the LV filling 
volume during the active phase [Spencer et al. 2001].  
 
Structurally, the LA typically undergoes dilatation on prolonged exposure to increased 
haemodynamic load. The giant LA in association with mitral valve disease, which was 
described over 150 years ago [Plaschkes et al. 1971], is an extreme example. However, 
the LA is exposed to the (diastolic) haemodynamic changes in the left ventricle even in 
the absence of significant mitral valve disease, due to the close anatomical and 
functional coupling of these two chambers. Hence, an increased LA size has been 
consistently reported in patients with hypertension and patients with heart failure 
(regardless of ejection fraction) [Takemoto et al. 2005]. By extension, an increased LA 
size, presumably reflecting the chronicity and severity of the adverse haemodynamic in 
the left ventricle is associated with increased cardiovascular event rates in patients with 
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coronary artery disease, hypertension and heart failure [Abhayaratnaet al. 2006, Tsang 
et al. 2002, Tsang et al. 2003]. 
 
The American Society of Echocardiography and European Association of 
Echocardiography have produced specific recommendations on LA assessment [Lang 
et al. 2005]. These guidelines recommend either using the prolate-ellipsoid, biplane 
area-length or the biplane Simpson’s method in the assessment of LA size. (Figure 1) 
 
1.3.1 M-mode anteroposterior dimension 
The M-mode anteroposterior dimension (AP) is measured from the leading edge of the 
posterior aortic wall to the leading edge of the posterior LA wall at the parasternal long 
axis view. As a surrogate measure of LA size, a consistent relationship between the AP 
diameter and other LA dimensions as it enlarges is assumed. However, LA enlargement 
often occurs preferentially in the superior-inferior or medial-lateral axis, as the LA is 
constrained by the aortic root (and to some extent, the right ventricular outflow tract) 
anteriorly, and the relatively rigid tracheal bifurcation posteriorly [Lemire et al. 1976]. 
Therefore, the changes in AP diameter may not be proportionate to and often 
underestimate changes in other LA dimensions [Lester et al. 1999]. This may explain 
the greater predictive value of LA volume for cardiovascular events in comparison with 
LA AP diameter [Tsang et al. 2002, Pritchett et al. 2003, Tsang et al. 2006]. 
 
Despite this fundamental limitation, previous studies have shown the association 
between increased AP dimension by M-mode measurement and the development of AF 
[Sanfilippo 1990, Vaziri et al. 1994, Psaty et al. 1997, Dittrich et al. 1999]. In the 
Framingham Heart Study[Vaziri et al. 1994], a 5 mm incremental increase in the AP 
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LA diameter on M-mode was associated with a 39% increased risk for developing AF 
during follow up. Similarly, the Cardiovascular Health Study [Psaty et al. 1997] 
reported a four-fold increase in the risk of developing AF in patients with an AP LA 
diameter of >5.0 cm. Increased AP LA dimension has also been associated with 
increased risk of stroke [Caplan et al. 1986, Di Tullio et al. 1999, Osranek et al. 2005] 
and cardiovascular mortality [Benjamin et al. 1995, Gardin et al. 2001, Laukkanen et al. 
2005]. 
 
1.3.2 Ellipsoid method 
The ellipsoid model assumes that LA can be adequately represented as a prolate ellipse, 
and LA volume can thus be approximated by the equation: π/6 (LxD1xD2), where L is 
long-axis from apical four-chamber, D1 is the AP dimension from the parasternal long-
axis and D2 is the medial-lateral dimension from apical four-chamber 
[Khankirawatanaet al. 2004]. A simplified version which substitutes D2 with the septal-
lateral dimension from apical four-chamber view has been reported [Pritchett et al. 
2003]. This method is also known as biplane dimension-length method. LA volume 
derived from this ellipsoid method was an independent (albeit relatively weak) 
predictor of total mortality in 109 patients with ischaemic cardiomyopathy, after 
adjusting for clinical and echocardiographic variables (hazard ratio of 1.03, 95% CI 
1.001 – 1.057, p=0.03) [Sabharwal et al. 2004]. Another study found that LA volume 
decreased significantly following successful direct current cardioversion to sinus 
rhythm in patients with atrial fibrillation from 38.5 ml to 21.7 ml at three months and 
19.6 ml at six months, following cardioversion of AF (p<0.02 for both) [Welikovitchet 
al. 1994].  
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1.3.3 Biplane area-length method 
The biplane area-length method has been proposed to overcome the limitations of 
single plane measurements. This biplane area-length method is based on the following 
equation: 8(A1)(A2)/3π(L), where A1 and A2 are the maximal LA area from the apical 
four-chamber and two-chamber views respectively, and L is the LA long-axis length 
measured from the middle of the plane of the mitral annulus to the superior aspect of 
the LA [Lang et al. 2005]. The LA long-axis length, L, is measured in both four-
chamber and two-chamber views, and the shorter of these is used in the formula.  
 
Using this biplane area-length method, population study had shown that an increase in 
LA volume is associated with the development of AF [Tsang et al. 2001]. Similarly, 
other investigators have demonstrated an association between LA volume by the 
biplane area-length method and the development of AF. [Table 1.1] 
 
1.3.4 Simpson’s method 
The LA volume can also be measured by using the Simpson’s method of discs, which 
states that the volume of a geometrical figure can be calculated from the sum of the 
volumes of the smaller figures of similar shape. This measurement assumes that the LA 
is oval in shape and the total volume as a series of stacked oval discs can be derived 
with the formula: volume = π/4(h)∑(D1)(D2), where h is height of the discs and 
orthogonal minor and major axes are D1 and D2 respectively. The volume calculation 
is normally performed with the aid of the computer software. The guideline suggests 
the use of Biplane Simpson’s method (apical 4-chamber and apical 2-chamber) to 
derive LA volume [Lang et al. 2006]. The biplane measurement makes fewer geometric 
assumptions and therefore is more accurate. However, another study had shown that the 
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monoplane (apical-4 chamber) disc measurement had a strong correlation with biplane 
measurement of LA volumes (r=0.97, p<0.001) [Lester et al. 1999].Both monoplane 
and biplane Simpson’s methods of LA volume measurements had been studied and 
reported in various patient populations [Losi et al. 2004, Toh et al. 2010]. 
 
1.3.5 Measurement pitfalls 
There are some common pitfalls on applying ellipsoid, area-length method and 
Simpson’s method for the measurement of LA volume. Firstly, as with any 
echocardiographic measurement, the image quality must be optimised with the 
appropriate imaging plane and clear LA border. Secondly, the LA appendage and the 
confluence of the pulmonary veins should be excluded from the measurement. Thirdly, 
the measurement of the long axis LA length is prone to error. This long axis 
measurement should be consistently measured to the mitral annular plane. Finally, 
maximal LA volume should be obtained at the end of ventricular systole, just prior to 
the opening of mitral valve. Poor image quality will either underestimate or 
overestimate the LA volume.  
 
Some studies have compared these three methods of LA volume measurement. In the 
study by Ujino et al. [2006], LA volume was measured by 2 independent operators 
using 3 methods (ellipsoid, area-length method and Simpson’s method) in 631 patients. 
This study showed that all 3 methods are highly reproducible: the inter-observer 
variability for ellipsoid, biplane area-length, Simpson’s methods (indexed to body 
surface area) were 4.0±3.5, 3.0±3.0 and 3.5±3.6 ml/m2 respectively, and the intra-
observer variability for these methods were 4.2±3.5, 2.8±2.9 and 3.4±3.5 ml/m2 
respectively. However, the mean LA volume indexes were 32±14 ml/m2 by the 
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ellipsoid method, 39±14 ml/m2 with the area-length method, and 38±13 ml/m2 with the 
Simpson’s method. The ellipsoid method consistently yielded smaller LA volume, and 
the correlation with area-length and Simpson’s method were 0.86 and 0.85 respectively, 
whilst the correlation between area-length and Simpson’s method was excellent 
(r=0.98). 
 
Similarly, Jiamsripong et al. [2008] studied the 3 methods of LA volume measurement 
in 97 patients. The mean LA volume indexed to body surface area were 27±12 ml/m2 
for ellipsoid method, 37±16 ml/m2 for area-length method, and 34±14 ml/m2 for 
Simpson’s method, with good reproducibility. Left atrial volumes by the ellipsoid 
method were consistently smaller than the area-length or Simpson’s method and the 
difference was most pronounced at larger LA volumes.   
 
The systematic difference in LA volume between the ellipsoid compared to the area-
length and Simpson’s method may be related to the dependence on the anteroposterior 
dimension in the former. Disproportionate increase in the medial-lateral and superior-
inferior compared to the constrained AP dimension will result in greater increase in LA 
volumes derived by the area-length and Simpson’s method, both of which are not 
dependent on measurement in the AP dimension. Hence, despite good reproducibility, 
measurement of LA volume by either area-length or Simpson’s method is 
recommended [Lang et al. 2005]. 
 
1.4 Atrial Fibrillation in Pacemaker Population 
 
1.4.1 Effects of Pacing and Cardiac Remodelling 
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Cardiac pacing is an effective treatment in the management of patients with brady- and 
tachy-arrhythmias [Epstein et al. 2008, Vardas et al. 2007]. Symptomatic bradycardia 
caused by sick sinus syndrome and atrioventricular (AV) conduction abnormalities are 
the two main indications for cardiac pacing. Indeed, pacing is the only effective 
treatment in these conditions. Newer indication for pacing such as biventricular pacing 
for drug-refractory heart failure has also been introduced [Vardas et al. 2007].  
 
The incidence of pacemaker implantation has increased significantly over the last few 
decades. The implantation of dual-chamber system has increased from 18.6% in 1980-
84 to 71.2% in 2000-2004 [Uslan et al. 2008]. In general, both right atria (RA) and 
right ventricle (RV) pacing are well tolerated and effective. RA lead is usually placed at 
the right atrial appendage, while the RV lead tends to be placed at the apex. However, it 
has been suggested that RV apical pacing either as single chamber (VVI mode) or dual 
chambers (DDD mode) may have detrimental effects on cardiac structure and function 
(remodelling), probably as a result of abnormal electrical and mechanical activation of 
the left ventricle (LV) [Sweeney and Prinzen 2006]. On the other hand, single chamber 
RA pacing as the mode of AAI is deemed ‘more physiological’ as ventricular activation 
occurs via the intrinsic conduction system. Numerous studies have tried to investigate 
the effect of different pacing sites and modes on cardiac remodelling to identify the 
‘ideal’ pacing site and/or mode.  
 
1.4.2 Right Ventricular Pacing and its Physiological Effect 
Conventional RV pacing from the apex has become the most commonly used site 
because of the ease of transvenous approach and the achievable stability of the lead 
position. However, RV apical pacing appears to be haemodynamically unfavourable 
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[Prinzen and Peschar 2002]. Cardiac pacing from the RV apex produces a slow 
depolarisation wave through the myocardium instead of specialised conduction tissue. 
This depolarisation wave, which results in depolarisation from the apex to the base and 
from the right to the left ventricle, is a reversal of the intrinsic ventricular activation 
[Karpawich and Mital 1997]. This abnormal pattern of depolarisation leads to increase 
activation time (broad QRS complex on surface ECG) with delayed activation of the 
lateral wall of the left ventricle (LV) that resembles left bundle branch block [Vassallo 
et al. 1986]. 
 
Animal studies have shown that the changes in electrical activation of the ventricles 
altered the pattern of mechanical contraction as well as the time of onset of contraction 
[Badke et al. 1980, Prinzen and Peschar 2002]. The region near the pacing site contracts 
early with passive stretching of the late-activated regions [Prinzen et al. 1999]. These 
late-activated regions then undergo vigorous contraction (greater regional loading) and 
impose a late systolic stretch on the early activated (now relaxing) sites. This abnormal 
stretching pattern of contraction within the LV leads to less effective overall 
contraction [Baller et al. 1988, Prinzen et al. 1999] and reduce contractility and 
function [Lee et al. 1994, Tse and Lau 1997]. The differences in contraction pattern 
result in redistribution of mechanical work, myocardial strain, perfusion pattern and 
oxygen demand within the LV wall [Baller et al. 1988, Delhaas. 1994, Lee et al. 1994, 
Prinzen et al. 1990, Prinzen et al. 1999]. Some studies suggested up to 65% of patients 
who need long term RV pacing showed myocardial perfusion defect at the pacing site 
even in the absence of coronary artery disease [Tse and Lau 1997, Skalidis 2001].  
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Right ventricular pacing also results in structural changes within the LV in the form of 
asymmetrical wall thickness and dilatation (remodelling) [Prinzen et al. 1995, Van 
Oosterhout et al. 1998, Vernooy et al. 2006]. A study also demonstrated long term RV 
pacing has effect on both cellular and intracellular changes which include 
mitochondrial variations and fibrosis [Karpawich et al. 1999] Another study by Spragg 
et al. [2003] showed the most profound cellular derangement occurred in the late-
activated region which had the most-hypertrophied myocardium. In addition, RV 
pacing can also induce both interventricular dyssynchrony (RV and LV) and 
intraventricular dyssynchrony (within LV) [Tops et al. 2006].  
 
1.4.3 Pacemaker and Atrial Fibrillation 
The development of AF in pacemaker population has been reported by numerous 
studies. A study of 177 patients with sick sinus syndrome showed greater left atrial 
dilatation and higher incidence of newly detected AF (24% in DDDR versus 7% in 
AAIR) over 2.9 years of follow-up [Nielsen et al. 2003]. Furthermore, the incidence of 
AF is also higher in patients with single chamber ventricular (VVI) pacing systems 
when compared to dual chamber or atrial pacing systems. Despite these observed 
differences in the incidence of AF, randomised studies have consistently failed to 
demonstrate differences in cardiovascular outcomes between dual chamber and single 
chamber ventricular pacing system [Connolly et al. 2000, Lamas et al. 2002, Toff et al. 
2005]. A recent meta-analysis of clinical trials confirmed a significantly lower 
incidence of AF with atrial-based pacing compared to ventricular pacing and a modest 
reduction in stroke, but there was no clear relationship between the reduction of 
incidence in AF and stroke [Healey et al. 2006].  
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This discordance in the incidence of AF and thromboembolic complications in the 
pacemaker population is even more perplexing in view of the well documented 
clustering of stroke at the time of AF onset, and further challenges the simplistic 
concept of a direct cause-effect relationship between AF, a prothrombotic state and 
thromboembolism [Wolf et al. 1983].  The higher incidence of AF with ventricular 
pacing, particularly in single chamber devices may be related to atrio-ventricular 
dyssynchrony, either obligated by single chamber ventricular pacing or as a 
consequence of non-physiological programming of AV delay, either at rest or on 
exercise [Israel 2006]. Long-term asynchronous ventricular pacing has been shown to 
cause atrial electrical remodelling and increased atrial dimensions [Nielsen et al. 1998, 
Sparks et al. 1999].  
 
However, an analysis of the MOST trial demonstrated a linearly increasing risk of AF 
with cumulative percentage ventricular pacing in DDDR and VVIR modes up to 80% 
to 85% [Sweeney et al. 2003]. The magnitude of increased risk was 1% for each 1% 
increase in cumulative percentage ventricular pacing and was similar between pacing 
modes. This increased risk of AF associated with increased ventricular pacing in both 
modes persisted despite statistical adjustments being made to account for the baseline 
predictors of AF. This suggests that right ventricular apical pacing, even in the presence 
of atrioventricular synchrony, may be related to an increased risk of AF through the 
development of interventricular dyssnchrony as described previously. 
 
The exact mechanisms by which RV pacing increases the incidence of AF are not fully 
understood. Abnormal ventricular activation with reduction in contractile function, the 
development of functional mitral regurgitation and consequent increase in atrial 
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pressure and size may be contributory [Calkins et al. 1992, Kanzaki et al. 2004, Klein et 
al. 1990]. Single chamber RV pacing (VVI mode) may cause retrograde conduction, 
discoordinated atrial and ventricular activation with permanent or intermittent atrial 
contraction against a closed AV valve can increase atrial pressure and pulmonary veins 
distension. This effect on pulmonary veins may act as a strong trigger for AF.  
 
Dual chamber pacing (DDD) attempts to reproduce physiological atrioventricular 
synchrony and eliminate retrograde conduction. However, in the MOST study 
[Sweeney et al. 2003] the risk of AF was similar between VVI and DDD mode. This 
suggests atrioventricular conduction also plays a role in AF development. An 
inappropriately short AV delay may result in ventricular activation before completion 
of atrial contraction resulting in truncation of atrial contribution to ventricular filling. 
Inappropriately long AV delay may result in atrial contraction coincident with the 
preceding ventricular activation or diastolic mitral regurgitation [Alizadeh et al. 2011, 
Barold et al. 2006, Okamoto et al. 1989]. Atrial pressure increases in both clinical 
scenarios and may drive atrial remodelling. 
 
Gulmez et al. [2009] and Sanagala et al. [2011] had studied the effect of RV pacing 
with LA remodelling with contrasting result. The LA volume and emptying mechanics 
showed no significant differences at baseline and after 4 hours of pacing [Gulmez et al. 
2009]. However, impaired LA emptying and changed in LA volume were noted during 
RV pacing in the other study [Sanagala et al. 2011]. 
 
1.5 Pacemaker Detected Atrial High Rate Episodes 
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1.5.1 Atrial High Rate Episodes and Atrial Fibrillation 
In approximately in 25% of elderly patients with AF, the arrhythmia appears to be 
intermittent with varying temporal patterns of presentation [Hart et al. 2000]. Despite 
this the risk of stroke is comparable regardless of whether the arrhythmia is 
paroxysmal, persistent or permanent [Hughes and Lip 2008]. A clear limitation in 
correlating the risk of stroke with this clinical scheme of classifying AF burden is that a 
significant proportion of patients remain asymptomatic during recurrences of AF [Page 
et al. 1994]. Thus, stroke or systemic embolism may be the first manifestation of AF in 
these patients [Rho and Page 2005]. Indeed, asymptomatic AF has been proposed as a 
reason for the higher incidence of stroke in the rhythm control arm of the AFFIRM trial 
[Flacker et al. 2005]. 
 
In contrast, contemporary pacemaker and other implantable cardiac rhythm devices that 
incorporate an atrial lead allow the storage of atrial high-rate episodes (AHRE), and 
potentially detailed characterisation of AF recurrences. The accuracy of device-detected 
AHRE is influenced by numerous factors such as atrial lead position, atrial lead 
configuration, atrial high rate settings, blanking periods, atrial sensitivity and changes 
in atrial signal amplitude during AF [Nowak et al. 2001, Passman et al. 2004, 
Purerfellner et al. 2004]. Pollak et al. showed that the detection of AHRE correlates 
well with ECG- documentation of AF, especially if higher atrial rates of >250 
beats/min and episodes of longer duration (>5 minutes) are used. Shorter episodes at 
lower rates often represent far-field R wave over-sensing [Pollak et al. 2001]. Up to 
88% of the stored AHRE were confirmed as AF in the study. Other studies have also 
reported on the low incidence of false positive detections with appropriate pacemaker 
programming [Fitts et al. 2000] and the accuracy of mode-switching episodes for AF in 
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the setting of good atrial sensing parameters [Passman et al. 2004]. Hence, device-
detected AHREs, when appropriately defined may be reliable estimates of AF episodes. 
 
The incidence of AHRE has been variably reported ranging from 24% to 88%, which 
can be partly explained by the different criteria used to determine AHRE as well as 
different study populations. (Table 1.2) Patients with pre-existing AF tend to have 
higher frequency of AHRE and greater AF burden. Most of the AHRE are 
asymptomatic even with incidence of as high as 88% on patients with prior atrial 
tachyarrhythmias [Cheung et al. 2006]. About 25% of AHRE detected in patients with 
previous history of atrial tachyarrhythmias during the follow up period were related to 
symptoms; for those without previous history of atrial tachyarrhythmias, only 1% of 
AHRE detected were related to symptoms [Ghali et al. 2007]. These observations 
highlight the limitations of symptom-based characterisation of AF episodes.   
 
1.5.2 Clinical implications of AHRE 
Clinical studies suggest that AHRE is associated with adverse clinical outcomes. 
Glotzer et al. investigated patients with permanent pacemakers or implantable 
defibrillators that are able to monitor AF burden (longest AF duration in any day over 
30 days window) and at least 1 risk factor for stroke [Glotzer et al. 2009]. The annual 
thromboembolic event risk was similar (1.1%) between patients with zero AF burden 
and low AF burden (<5.5 hours). However, patients with high AF burden (> or = 5.5 
hours) had thromboembolic event risk of 2.4% over 1 year. The hazard ratio was 2.20 
(95% CI 0.96 to 5.05, p=0.06) when compared with patients with zero burden. 
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A sub-study of 312 patients from the MOde Selection Trial (MOST) showed a 
correlation between pacemaker detected AHRE and clinical outcomes [Glotzer et al. 
2003]. In this study, patients with at least 1 AHRE of more than 5 minutes in duration 
had a 5.93-fold higher risk of developing AF (p=0.0001), 2.79-fold higher risk of death 
or nonfatal stroke (p=0.0011) and 2.48-fold higher probability of total mortality 
(p=0.009). Similarly, Capucci et al. showed that device-detected AF duration of more 
than 1 day was associated with 3.1-fold risk of ischaemic stroke, transient ischaemic 
attack and embolic events [Capucci et al. 2005].  
 
In patients with cardiac resynchronization therapy, Borleffs et al. showed that 25% of 
patients over a mean follow-up duration of 32 ± 16 months developed AF (AHRE >180 
beats per minute for > 10 minutes/day) [Borleffs et al. 2009]. Patients who developed 
AF experienced more hospitalizations for heart failure, more inappropriate shocks for 
ventricular arrhythmias and less improvement in left ventricular function.  
 
1.6 Atrial fibrillation, atrial high-rate episodes and thrombogenesis markers 
 
1.6.1 Thrombogenesis markers in AF 
The thrombogenesis in AF mainly fulfil all components of Virchow’s triad. Thrombosis 
markers related to abnormal blood constituents, blood vessel wall and blood stasis have 
well been established and studied in AF population [Watson et al. 2009, Becker 2005]. 
Inflammation also plays an important role in the initiation and perpetuation of AF 
[Boos et al. 2006, Issac et al. 2007]. Watson et al. had also proposed the changes related 
to inflammation and coagulation during AF [Watson et al. 2009]. Biomarkers which are 
related to these changes can be mainly categorised into 4 main activities. (Table 1.3)  
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1.6.2 Inflammatory activity 
Serum inflammatory markers have been investigated by numerous clinical studies in 
relation to atrial fibrillation. Among these, CRP and IL6 were extensively studied. 
(Table 1.4) Besides the raised inflammatory markers in AF population, Conway et al 
also confirmed the prognostic significant of raised CRP and IL-6 in AF population 
[Conway et al. 2004]. These studies have proved that inflammation and AF is closely 
related.  
 
1.6.3 Platelet activity 
Platelet activation is most prominent at the sites of vascular or endocardial injury. It is a 
fundamental step in thrombin generation. Soluble P-selectin is found predominantly in 
platelets and can be measured in the plasma [Blann et al. 2003]. The studies involved P-
selectin and AF showed conflicting results. Sohara et al. [1997] demonstrated that 
patients with paroxysmal AF had detectable P-selectin levels within 12 hours of 
arrhythmia onset. This activation persisted even longer in patients with more sustained 
AF. However, Choudhury et al. confirmed a raised level of P-selectin in AF group 
when compared with healthy controls, but the study failed to establish the level of P-
selectin with AF and concluded the raised level could be a reflection of other 
cardiovascular morbidities [Choudhury et al. 2007a, 2007b].  
 
Evidence of platelet activation can also be estimated by plasma level of β-
thromboglobulin and platelet factor 4 (PF4) which are both released from platelet alpha 
granules and specific to platelets [Schernthaneretal 1979]. Raised level of β-
thromboglobulin had been shown in AF patients [Lip et al. 1996, Li-Saw-Hee et al. 
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2000]. However, study by Ludlam et al. [1979] failed to show any correlation between 
plasma β-thromboglobulin and venous platelet counts. Activated platelets undergo 
adhesion, subsequently leads to platelet aggregation. Platelet adhesion to 
subendothelium is mediated by a number of proteins in the plasma, of which the more 
important ones are von Willebrand factor (vWf) and fibrinogen [Packham and Mustard 
1984]. vWf is synthesized by the endothelium and is released in endothelial damage. 
Thus, vWf is a marker of endothelial dysfunction and inflammation [Freestone et al. 
2010]. The association of vWf and AF was evident in the Rotterdam study [Conway et 
al. 2003a]. A different study by Conway et al on the prognostic significant of vWf and 
P-selectin in non-valvular AF patient yielded mix result [Conway et al. 2003b]. In this 
study, level of vWf was significant predictor for stroke and vascular event but not the 
P-selectin level.   
 
1.6.4 Thrombin activity 
Plasma markers of thrombin activity such as prothrombin activation fragment 1+2 
(F1+2) and thrombin-antithrombin III complexes (TAT) has been shown to rise in AF 
patient [Asakura et al. 1992]. Three contemporary studies of thrombin activity in AF 
patients showed raised F1+2 and TAT when compared with patients in sinus rhythm 
[Roldánet al. 2003, Acevedo et al. 2005, Pérez et al. 2002].   
 
1.6.5 Fibrinolytic activity 
Fibrinolytic system on the coagulation cascade plays an important role in preventing 
intravascular thrombosis [Collen and Lijnen 1991]. Components on fibrinolytic system 
can be used as markers to investigate fibrinolysis and/or thrombogenesis. There were 
evidence to show that increases level of tissue-type plasminogen activator (t-PA) 
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antigen and tissue-type plasminogen activator inhibitor-1 (PAI-1) were associated with 
acute coronary syndrome, stroke, peripheral vascular disease and AF [Marin et al. 
2003].   
 
Fibrinogen is the precursor of fibrin, an important clotting factor. Indeed, fibrinogen 
plays an important role during inflammation and thrombogenesis [Kamath and Lip 
2003]. It is a major acute phase protein, and helps increase plasma viscosity, and 
modulate endothelial function. Fibrinogen is also a substrate for thrombin, involved in 
the final step of coagulation cascade, as well as an important protein for platelet 
aggregation and stabilisation of thrombus formation. Large population based studies 
had shown that level of fibrinogen is associated with cardiovascular morbidities and 
mortality and concluded that fibrinogen was an independent cardiovascular risk factor 
[Ernst and Resch 1993, Maresca et al. 1999]. Korantzopoulos et al. has showed raised 
level of fibrinogen along with CRP in persistent AF patient who relapsed into AF 
compared to patients who remain in sinus rhythm [Korantzopoulos et al. 2005].  
 
D-dimer is a plasma marker for thrombogenesis and a sensitive marker of fibrin 
turnover which allowed the recognition of activated coagulation [Lip and Lowe 1995]. 
Elevated D-dimer level had been shown in patients with AF, especially in patients with 
documented thrombus formation within the left atrial appendages [Nakajima 2000, 
Sakuraiet al. 2003]. D-dimer has also been used as prognostic tool in predicting 
cardiovascular and thromboembolic events [Nozawa et al. 2006, Vene et al. 2003]. Of 
note, D-dimer levels reduce significantly after treatment with warfarin [Lip et al. 1996].  
 
1.6.6 Thrombogenesis markers of paroxysmal versus permanent AF 
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Although these biomarkers have been proved to be elevated in general AF population, 
studies between temporal classifications of AF population (paroxysmal, persistent and 
permanent) showed mixed results. Li-Saw-Hee et al. [2001] showed that patients with 
PAF had similar P-selectin levels when compared with healthy individuals in sinus 
rhythm. The level of fibrinogen and vWf were elevated in PAF. In the same study, all 3 
thrombogenesis markers were significantly raised in permanent AF group. However, 
patient with persistent AF had normal level of p-selectin, fibrinogen and vWf. 
 
Kamath et al. [2002] studied level of D-dimer, fibrinogen, P-selectin and ß-
thromboglobulin in PAF, persistent and permanent AF population. Both ß-
thromboglobulin and D-dimer were elevated in all AF patients. Highest level was seen 
in permanent AF group. The levels of P-selectin and fibrinogen showed no difference 
in different AF group. In fact, their levels were similar to healthy controls. Another 
study by Motoki et al on TAT, PF4 and plasmin antiplasmin complex showed no 
significant difference between PAF and permanent AF patients [Motoki et al. 2009]. 
 
1.6.7 Thrombogenesis markers in AHRE 
AHRE on device interrogations have been shown to relate to the development of AF 
and thromboembolic events. However, recent study by Watson et al. [2010] failed to 
establish the relationship of thrombogenesis markers to AHRE detected in pacemaker 
population. There was no significant difference on biomarkers of thrombogenesis, such 
as P-selectin, vWf and tissue factor, in patient with high AF burden (>50%) in 
comparison to patients who were in sinus rhythm (0% AF burden). The authors 
conclude that the levels of thrombogenesis markers were probably related to underlying 
co-morbidities rather than AF burden per se. 
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1.7 Non-invasive assessment of interatrial conduction time 
 
Conduction of the sinus beat through the atria requires electrical and functional 
continuity of atrial myocytes. The electrical and structural changes to the atria (atrial 
remodelling) play an important role in the perpetuation and progression of atrial 
arrhythmias [Ausma et al. 2001, Wijffels et al. 1995]. The presence of triggers, short 
atrial refractory periods and delayed atrial conduction may promote the development of 
and sustaining atrial fibrillation [Cosio et al. 1983, Konnings et al. 1994, Platonov PG 
2007, Shimizu et al. 1989]. A number of studies suggest that prolongation of interatrial 
conduction time (IACT) may be a predisposing factor for the development of atrial 
tachy-arrhythmias and atrial conduction time has been proposed as a marker of atrial 
remodelling [Agarwal et al. 2003, Leier et al. 1978, Papageorgiu et al. 1996].  
 
Precise measurement of interatrial conduction time requires an invasive 
electrophysiology study. A numbers of non-invasive methods which include P-wave 
duration, P-wave signal-averaging technique, P-wave morphology and P-wave 
dispersion have been proposed in evaluating interatrial conduction time. Among these 
non-invasive methods, P-wave duration and morphology are frequently used as markers 
of atrial conduction [Dilaveris and Gialafos 2001, Stafford et al. 1991]. More recently, 
tissue Doppler imaging (TDI) on echocardiography has been proposed as a reliable 
method to evaluate atrial conduction time [Lind et al. 2002, Sutherland et al. 1999]. 
 
1.7.1 P-wave duration and P-wave signal-averaging 
P-wave duration is generally accepted as a reliable non-invasive marker of atrial 
conduction. The prolongation of P-wave on surface ECG maybe a result of underlying 
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coexisting condition such as heart failure, hypertension or structure abnormality of the 
atrial wall (atrial fibrosis) [Becker 2004, Nattel and Opie 2005]. P-wave duration can be 
measured on 12-lead electrocardiography (ECG) or more precisely with signal-
averaging ECG of P-wave (P-SAECG). P-wave duration measured from a single 
surface ECG has been shown to correlate significantly with the duration of the right 
atrial electrogram measured invasively [Liu et al. 1998]. P-wave duration of >120ms is 
generally considered wide [Ariyarajah and Spodick 2005].The Framingham Heart 
Study has demonstrated that the upper 5% of maximum P-wave duration (105±12ms) 
has a hazard ratio of 2.51 for long-term AF risk in the community by using a digital 
calliper P wave duration [Magnani et al. 2011]. 
 
P-SAECG requires amplification of the electrical signal, which allows more precise 
measurements of duration and amplitude of P-wave. The ability to record low 
amplitude and high frequency electrical signals as well as decreasing noise and artefact 
during recording is a major advantage of P-SAECG over standard ECG. P-SAECG 
takes 30 minutes to record. Using P-SAECG, advanced interatrial block with retrograde 
activation of the left atrium (seen as P duration >120ms and biphasic P-wave in the 
inferior leads of ECG) has been reported in patients with a history of atrial 
tachyarrhythmia [Abe et al. 1997, Agarwal et al. 2003, Bayes et al. 1985]. Fukunami et 
al. [1991] demonstrated a significant difference in P wave duration by P-SAECG in 
patients who developed atrial fibrillation (AF). In the study, the use of P-SAECG (P-
wave filtered at 40-300Hz of the spatial magnitude) had a specificity of 82% and 
sensitivity of 88% for identifying patients at risk of developing AF. Other studies also 
demonstrated the association of P-SAECG with the history of AF [Guidera and 
Steinberg 1993, Stafford et al. 1991], predicting the recurrence of AF after 
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cardioversion [Aytemir et al. 1999], the deterioration of paroxysmal AF to permanent 
AF [Abe et al. 1997] and the development of AF after bypass surgery [Steinberg  et al. 
1993,Tamis and Steinberg 1998]. Most the studies had different criteria to define P-
wave duration using the P-SAECG. 
 
The use of P-SAECG has improved the accuracy of measuring P-wave duration. 
However, the data on reproducibility filter settings, total number of beats to be 
averaged, the small amplitude of atrial ECG and the offset of P-wave all depends on the 
system used. For instance, Fukunami et al. [1991] used P-wave filtered at 40-300Hz of 
the spatial magnitude, whereas, Guidera and Steinberg [1993] used a more complicated 
orthogonal lead system, with QRS complexes as a trigger, and the total P-wave duration 
was measured before and after filtering with square fit filter. The P-wave durations 
were subsequently combined into a vector combination of orthogonal leads. Rosenheck 
has reported that using P-SAECG to predict the risk of AF has a relatively high 
negative predictive value (60-80%). However, the positive predictive value of P-
SAECG in predicting the risk of AF is considerably lower than the negative predictive 
value [Rosenheck 1997]. Majority of the studies on P-SAECG were in patients 
undergoing coronary bypass surgery or following myocardial infarction. Thus, the role 
of this technique in patients with paroxysmal AF without structural heart disease is 
more difficult to determine. 
 
1.7.2 P-wave dispersion 
A uniform prolongation of intra- and inter-atrial conduction time can be recognised by 
prolongation of surface P-wave duration on ECG. However, Spach and colleagues had 
demonstrated that the micro-architecture and the non-uniform properties of the atrial 
myocardium can cause inhomogeneous and discontinuous propagation of sinus 
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impulses [Spach and Dolber 1986, Spach et al. 1981]. The effect of atrial fibre 
geometry, along with other intracellular and intercellular factors account for the 
presence of site specific conduction delays, which play a major role in the initiation of 
re-entry wavelets in AF [Papageorgiou et al. 1996].  
 
Local site-specific conduction delay in atrial depolarisation may produce heterogeneous 
P-wave duration. Hence, a simple measurement of P-wave duration on surface 12 lead 
ECG or with P-SAECG would not account for the heterogeneity of local atrial 
conduction. Buxton and Josephson [1981] attempted to define local conduction delay 
by correlating the asynchronous atrial conduction with an iso-electric interval derived 
from surface ECG. This iso-electric interval was derived by subtracting the longest P-
wave duration from the total P-wave duration in any of the standard limb lead. The iso-
electric interval was found to be significantly higher in patients with history of AF in 
comparison with patients without AF (12.4ms vs 5.9ms, p<0.001). 
 
P-wave dispersion is defined as the difference between the longest and the shortest P-
wave duration in any of the 12 ECG leads [Dilaveris and Gialafos 2001]. Multiple 
studies had demonstrated the role of P-wave dispersion in predicting patients with AF 
(Table 1.5) [Aytemir et al. 2000,Ciaroni et al. 2000, Dilaveris et al. 1998, 1999a, 
1999b, 2000, Fan et al. 2000, Gilligan et al. 2000, Weber et al. 1998]. Tukek et al. 
[2000] demonstrated that the Valsalva manoeuvre normalised the increased P-wave 
duration and dispersion in patients with history of paroxysmal AF but increased P wave 
duration and dispersion in normal controls. This indicated performing Valsalva 
manoeuvre in patients with paroxysmal AF reduces the intra-atrial conduction. Reduced 
P-wave dispersion was demonstrated in patients who were given single dose of 
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disopyramide, and reduced P-wave dispersion with disopyramide was associated with 
suppression of AF attacks. In contrast, an increase in P wave dispersion was associated 
with multiple recurrences of AF [Kubara et al. 1999]. 
 
The methodology used in obtaining P-wave dispersion in the above studies varied. 
Some studies used digital signal-averaging system, others measured P wave dispersion 
manually on paper or high resolution computer screen from 12 or 16 ECG leads were 
used [Aytemir et al. 2000, Ciaroni et al. 2000, Dilaveris et al. 1998, 1999a, 1999b, 
2000, Fan et al. 2000, Gilligan et al. 2000, Weber et al. 1998]. Dilaveris and colleagues 
have reported a poor agreement between the manual on screen versus digitally 
measured P-wave dispersion, and the mean intra- and inter-observer variability can be 
as high as 20% [Dilaveris et al. 1999]. This has posed a question on reliability, 
accuracy and reproducibility on the methods of measuring P-wave dispersion.   
 
1.7.3 P-wave morphology 
P-wave morphology offers another source of information regarding atrial activation and 
propagation. P-wave morphology depends on: i) the origin of the rhythm that defines 
right atrial depolarisation vector, ii) left atrial breakthrough that defines left atrial 
depolarisation vector, iii) the shape and size of the atrial chambers that affect the time 
required for completion of the depolarisation process [Platonov 2012]. The complexity 
of different depolarisation vectors as well as involvement of Bachmann’s bundle is out 
of the scope of this review. 
 
Studies in the past had demonstrated the precordial bi-phasic P-wave (P-wave negative 
terminal force PTF) as a marker of atrial enlargement [Morris et al. 1964], interatrial 
conduction defect [Josephson et al. 1977], and associated with paroxysmal AF 
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[Robitaille and Phillips 1967]. In the Multicentre Automatic Defibrillator Implantation 
Trial II (MADIT II), the Type 2 P-wave morphology (the anterior to posterior 
activation of left atrium and biphasic P waves in correspondent leads) were 
significantly associated with the development of new AF during follow-up in 
comparison to Type 1 P-wave morphology (posterior to anterior activation of left 
atrium give rise to positive or isoelectric P-wave in correspondent leads) (p=0.04) 
[Holmqvist et al. 2009]. P-wave morphology analysis may also predict clinical 
outcomes beyond atrial fibrillation. Holmqvist et al. demonstrated that atypical P-wave 
morphology in MADIT II trial was independently associated with heart failure 
mortality [Holmqvist et al. 2010]. Bi-phasic P wave was found to be a predictor of poor 
prognosis in both acute phase of myocardial infarction [Karassi and Manu 1977, Mehta 
et al. 1997], and during follow up [Kentala et al. 1975, Pohjola et al. 1979] as well as 
the risk of stroke [Kohsaka et al. 2005]. 
 
1.7.4 Tissue Doppler Imaging (TDI) 
Tissue Doppler echocardiography directly measures myocardial velocities. Segmental 
left atrial myocardial function can be assessed from the longitudinal motion amplitude 
and velocity of the septal and lateral mitral annulus excursion during atrial systole. 
Similarly, right atrial myocardial function can be assessed from right atrial free wall 
near the tricuspid annulus. The atrial electromechanical delay is the time interval 
between the electrocardiography P wave and the atrial contraction detected by Doppler 
echocardiography. This is typically measured from the initiation of the P wave on 
electrocardiography to the peak A’ wave of the atrial tissue Doppler tracing (PA –TDI) 
interval. Hence, unlike the assessment of P waves in isolation, the atrial 
electromechanical delay measured from tissue Doppler echocardiography provides a 
measure of atrial conduction and mechanical activation time [Rein et al. 2003]. 
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The PA-TDI interval was an independent predictor of new onset of AF in general 
population (OR 1.375, p=0.027) [De Vos et al. 2009]. Muller et al. [2013] reported 
longer PA-TDI interval in patients who had early recurrent AF after successful direct 
current electrical cardioversion of persistent AF compared to patients who maintained 
sinus rhythm. A PA-TDI interval of 152ms achieved sensitivity of 87% and specificity 
of 100% for the recurrence of AF. Two studies reported the used of PA-TDI interval in 
predicting new onset of AF after cardiac surgery [Muller et al. 2013, Ozlu et al. 2013]. 
Both studies demonstrated a significant longer PA-TDI interval in patients with 
postoperative AF. At a cut-off value of 133ms, PA-TDI achieved sensitivity of 100% 
and specificity of 86% respectively for the development of AF [Ozlu et al. 2013]. 
Another study by Antoni et al. [2010] showed that PA-TDI duration is a simple 
measurement that predict new onset of AF after acute myocardial infarction. However, 
none of these studies have reported the inter- and intra-observer variability in the 
technique of measuring PA-TDI. 
 
This estimation of total atrial conduction time using transthoracic TDI of the atrial has 
been validated against other non-invasive interatrial conduction time measurements as 
well as invasive electrophysiology study (Table 1.6) [Antonini et al. 2011, Chao et al. 
2011, Emiroglu et al. 2011, Merckx  et al. 2005, Pekdemir et al. 2010]. More recently, a 
study by Deniz et al. [2010] found a weak correlation between interatrial conduction 
time with tissue Doppler and electrophysiogical techniques (r=0.308, p=0.002). In the 
same study, the intra-left atrial conduction time had a moderate correlation with 
electrophysiological measurement (r=0.652, p<0.001). 
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In summary, the PA-TDI interval measurement correlates with other measures of atrial 
conduction, and is associated with the development of AF. However, this method relies 
heavily on the detection of the P wave initiation. There may also be a minor delay in 
ECG processing on echocardiography machine. The impact of variable heart rate and 
loading conditions on the PA-TDI interval will also require further study. 
 
 
1.8 Conclusion 
 
Pacemaker detected AHRE is a reliable method to quantify AF disease burden. Early 
studies suggest that asymptomatic AHRE may be associated with significant adverse 
clinical events, but offer little mechanistic insight into the pathophysiology. In 
particular, patients with persistent pacing from the right ventricular apex are at 
increased risk of AF, but the relationship between right ventricular pacing with LA 
remodelling, indices of thrombogenesis and the development of AF remains unclear. 
 
The aim of my study is to investigate: 
(i) The inter-relationship between RV pacing, left atrial remodelling, atrial arrhythmia 
and indices of thrombogenesis in patients with dual chamber pacemakers. 
(ii) The relationship between interatrial conduction time and atrial arrhythmias. 
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Figure 1.1 Schematic presentations on methods of LA volume measurement 
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Table 1.1 Studies using the biplane area-length method in assessing the left atrium 
to predict AF and cardiovascular mortality 
 
Study; 
Year  
Study population Sample 
size 
Study outcome 
Casaclang-
Verzosa et 
al; 2010  
Elderly cohort with 
other AF risk 
factors 
800 Indexed LA vol was independent 
predictor of first AF (HR 1.3 per 5 
ml/m2, 95% CI 1.09-1.48, P=0.001). 
 
Fatema et 
al; 2009  
Elderly cohort in 
sinus rhythm 
574 Both minimal and maximal LA vols 
are independent predictor of first 
AF/flutter. 
 
Tanabe et 
al; 2007  
Patients with severe 
degenerative MR 
with SR 
66 LA vol index ≥ 75ml/m2 increased 
risk of developing AF (sensitivity and 
specificity of 88%). 
 
Osranek et 
al; 2006  
Patients for cardiac 
surgery 
205 LA vol index ≥ 32 ml/m2 was 
associated with 5 fold risk of 
developing post-operative AF. 
 
Osranek et 
al; 2005  
Lone atrial 
fibrillation 
46 LA vol index≥ 32 ml/m2 had 
significantly worse event-free survival 
during follow up. (HR 4.46; 95% CI 
1.56-12.74; p=0.005) 
Tani et al; 
2004  
Patients with 
hypertrophic 
cardiomyopathy 
141 LA vol was most sensitive and specific 
parameter for occurrence of PAF. 
 
LA= left atrial; vol= volume; AF= atrial fibrillation; HR= hazard ratio; CI= 
confidence interval; SR= sinus rhythm; TIA= transient ischaemic accident; PAF= 
paroxysmal atrial fibrillation; MR=mitral regurgitation 
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Table 1.2 The incidence of atrial high-rate episodes 
 
Study; year  N; mean age 
(years) 
AHRE 
criteria 
Follow up 
duration 
Incidence rate  
Defaye et al, 1998  
 
354; 70 ± 11 -- 1 month [179/354] 50.6% 
 
 
Gillis et al, 2002  231;  -- 718 ± 383 
days 
 
 
37% - 68% 
Glotzer et al, 2003  312; 74 Atrial 
rate 
>220 
bpm for 
> 5 mins 
 
27 months [160/312] 51.3%  
Schuchert et al*, 
2005  
239;  -- 12 months [73/239] 31% 
 
Cheung et al*, 
2006  
262; 74 ± 12 > or = 5 
mins 
596 ± 344 
days 
 
24% and 34% at 1 and 
2 years follow up 
Orlov et al, 2007  427 
(i) no prior AT 
- 331 
(ii) prior AT -– 
96 
 
--  
24 months 
 
(i) [178/331] 53.8%  
(ii) [85/96] 88.6 %  
Mittal et al*, 2008  1500 Atrial 
rate ≥ 
180 bpm 
≥ 5 min 
 
6 months [150/1500] 10.0% 
Quirino et al, 2009  102; 73 ± 7 > 30 s 16 ± 6 
months 
 
74% 
Ricci et al, 2009  166; 73 ± 10 Burden 
>10% 
for >5 
days 
488 ± 203 
days 
[42/166] 26% 
 
* Study population without previous atrial tachyarrhythmias 
AHRE = atrial high-rate episodes; AT = atrial tachyarrhythmias; bpm = beats per 
minute; mins = minutes;  
 
 
 
 
32 
 
 
Table 1.3 Biomarkers changes in atrial fibrillation 
Biomarker Changes in atrial 
fibrillation 
Endothelial inflammation 
von Willebrand factor  
Tissue factor  
Interlukin 6  
C-reactive protein 
 
Increase 
Increase 
Increase 
Increase 
Platelet activity 
Soluble P-selectin  
ß-thromboglobulin  
Platelet factor 4  
Platelet microparticles  
 
Increase  
Increase  
Increase  
Increase 
Thrombin activity 
Prothrombin  
Prothrombin fragment 1+2 
Thrombin antithrombin III 
complexes 
 
Increase  
Increase  
Increase 
Fibrinolytic activity 
Fibrinogen 
Tissue plasminogen activator 
Plasminogen activator inhibitor 
1 (PAI-1) 
Plasmin antiplasmin complex 
D-dimer 
 
Increase 
Increase 
Increase 
 
Decrease 
Increase 
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Table 1.4 Key studies investigating plasma inflammatory markers with atrial fibrillation 
Study, 
Year  
Markers Study 
design 
Subjects Results 
Freeston
e et al, 
2008  
vWf, E-
sel 
Case- 
control 
40 permanent 
AF vs 26 SR 
vWf and E-sel were higher in AF (p<0.05) 
Watanab
e et al, 
2006  
CRP Prospective 104 persistent 
symptomatic 
AF 
CRP predicts successful cardioversion and maintenance of SR 
Freeston
e et al, 
2005 
vWf, E-
sel, 
thrombom
odulin, 
CECs 
Case- 
control 
28 permanent 
AF vs 20 
healthy 
vWf was higher in AF (p<0.001) 
Asserber
gs et al, 
2005  
CRP, 
microalbu
minuria 
Cross-
sectional 
8501 all AF Both CRP and microalbuminuria were independent associated 
with AF 
Psychari 
et al, 
2005  
CRP, IL-6 Case-
control 
46 persistent 
and permanent 
AF vs 90 sinus 
rhythm 
CRP and IL-6 greater in AF than in controls 
Watanab
e et al, 
2005  
CRP Case-
control 
50 paroxysmal 
AF vs 50 
control in 
sinus rhythm 
CRP greater in PAF than controls 
Anderso
n et al, 
2004  
CRP Retrospecti
ve 
347 all AF vs 
2449 control 
group 
CRP elevated with AF 
Sata et 
al. 2004  
CRP, IL-
6, TNF-α 
Case-
control 
15 paroxysmal 
AF vs 11 sinus 
rhythm 
CRP, IL-6, TNF-α were markedly elevated in AF group; 
cardioversion failed to revert CRP level 
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Conway 
et al, 
2004 
CRP, IL-
6, TF. 
vWf, P-sel 
Case-
control 
41 permanent 
AF vs 106 
healthy control 
Levels of CRP, IL-6, TF were higher in AF group than control 
Aviles et 
al, 2003 
CRP Cross-
sectional 
and 
longitudina
l 
Cross-
sectional – 
5806; 
longitudinal – 
5491  
CRP associated with presence of AF and development of AF 
Sanchez 
et al, 
2003  
CRP Observatio
nal 
498 ACS 
patients 
CRP level independently predicts new onset of AF 
Acevedo 
et al, 
2003  
CRP Case 
control 
cross-
sectional 
and 
longitudina
l 
Cross-
sectional – 
109; 
longitudinal – 
68  
Elevated CRP levels at baseline and follow up in AF group 
compared with SR 
Chung et 
al, 2001  
CRP Observatio
nal case 
control 
131 
paroxysmal 
and persistent 
AF vs 71 sinus 
rhythm 
CRP elevated in AF group; more in persistent vs paroxysmal 
AF 
Dernellis 
and 
Panareto
u, 2001  
CRP Case-
control 
50 paroxysmal 
AF vs 50 
controls 
CRP elevated in AF 
 
AF – atrial fibrillation; SR – sinus rhythm; vWf – von Willebrand factor; E-sel – soluble E-selectin; CECs – circulating endothelial cells; 
IL-6 – interlukin 6;  TNF-α – tumour necrosis factor- α; P-sel – soluble P-selectin ; 
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Table 1.5 Studies on P wave dispersion in predicting atrial fibrillation  
 
Study, year  Population No of 
patients 
Outcome 
Aytemir et 
al, 2000  
Lone AF 160 Sensitive and specific ECG 
predictor of paroxysmal lone AF. 
P wave dispersion significant 
correlated with maximum P 
wave duration (r=0.702, 
p<0.001). 
 
Ciaroni et 
al, 2000  
Hypertension 97 Significantly increased P wave 
dispersion in patient developing 
AF (48 ± 14ms vs 30 ± 8ms, 
p<0.01). P wave dispersion was 
an independent predictor for 
onset of AF (OR 2.81, p<0.001). 
 
Dilaveris et 
al, 1998  
Lone AF 100 Significantly increased P wave 
dispersion in lone AF (49 ± 15ms 
vs 28 ± 7ms, p<0.001). Relative 
risk of AF recurrence was 2.37 
for a P wave dispersion ≥40ms). 
 
Dilaveris et 
al, 1999  
CAD 95 Significant higher P wave 
dispersion during angina 
episodes. 
 
Dilaveris et 
al, 1999  
Hypertension 110 P wave dispersion significantly 
higher in PAF as compared to 
controls. P wave dispersion was 
positively correlated with 
maximum P wave duration and 
negatively correlated with 
minimum P wave duration. 
Dilaveris et 
al, 2000  
Mixed HD 88 P wave dispersion was shown to 
be significant predictor of 
frequent symptomatic AF 
episodes. 
 
Fan et al, 
2000  
Post-CABG 132 Biatrial pacing prevent 
postoperative AF by significantly 
reduced mean P wave dispersion 
(42% ± 8%) when compared 
with single site (LA pacing 13% 
± 6%, RA pacing 10% ± 9%, 
both p<0.05). 
 
Gilligan et 
al, 2000  
Atrial pacing 48 P wave duration significantly 
reduced in biatrial pacing group. 
P wave dispersion unaffected. 
 
Weber et al, 
1998  
Post-CABG 107 P wave dispersion significantly 
increased in patients developing 
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AF post CABG as compared to 
controls (49 ± 12ms vs 41 ± 
12ms, p<0.001). P wave 
dispersion a significant predictor 
of post-operative AF. 
 
 
AF = atrial fibrillation; CAD = coronary artery disease; HD = heart disease; CABG = 
coronary artery bypass graft; LA = left atrial; RA = right atrial  
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Table 1.6 Validation studies on tissue Doppler imaging of atrial conduction time 
with other techniques 
 
Study, year Interatrial conduction time 
measurement 
Correlation 
Merckx et al, 
2005  
P-wave duration on 
SAECG 
Good correlation, 
r=0.91, p<0.001 
Emiroglu et al, 
2011  
P-wave dispersion Good correlation, 
r=0.72, p<0.001 
Pekdemir et al, 
2010  
P-wave dispersion Good correlation, 
r=0.56, p<0.001 
Chao et al, 2011  Invasive EP study Good correlation, 
r=0.55, p<0.001 
Antonini et al, 
2011 
Invasive EP study Good correlation, 
r=0.92, p<0.001 
 
SAECG = signal-averaging ECG; EP = electrophysiology 
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CHAPTER 2: METHODOLOGY 
 
 
 
2.1 Background 
 
In Chapter 1, I have summarised that importance of echocardiographic measurement of 
left atrial (LA) remodelling and its clinical implication especially in population with 
atrial fibrillation (AF). However, the relationship between LA volume and diameter are 
non-linear, and the former is superior in predicting cardiovascular outcomes such as AF 
[Pritchett et al. 2003, Tsang et al. 2001, Tsang et al. 2006]. Besides LA volume 
measurement, strain rate imaging has emerged as a quantitative technique to assess 
myocardial function and contractility.  Left atrial strain rate (SR) imaging has been 
applied to the assessment of LA function. The use of transthoracic echocardiography 
with tissue Doppler imaging (TDI) and SR imaging in hypertension with or without AF 
suggests LA remodelling may occur prior to the development of AF [Wang et al. 2007]. 
 
I have also summarised the disease burden and health care burden poses by AF [Kannel 
et al. 1998, Lloyd-Jones et al. 2004, Miyasaka et al. 2006]. The use of contemporary 
pacemaker and other implantable cardiac rhythm devices that incorporate an atrial lead 
allow the storage of atrial high-rate episodes (AHRE), and potentially detailed 
characterisation of AF burden was also discussed. AHRE correlates well with ECG- 
documentation of AF, especially if higher atrial rates of >250 beats/min and episodes of 
longer duration (>5 minutes) are used [Pollack et al. 2001]. 
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The current data suggest a number of mechanisms contribute to the development of AF 
in the general population as well as patients with pacemakers. Echocardiographic 
parameters of LA remodelling have not been investigated in the latter population. It 
also remains unclear how pacing correlates with LA remodelling and indices of 
thrombogenesis both prior to the development of AF and the prospective AF burden. 
 
 
2.2 Hypotheses and Study Design 
 
The first part of this thesis will investigate the inter-relationship between LA 
remodelling, atrial arrhythmia burden and plasma indices of thrombogenesis in patients 
with dual chamber pacemakers. The following hypotheses will be tested: 
 
1. The development of AF is associated with adverse parameters of LA 
remodelling in the pacemaker population. 
 
2. The adverse LA remodelling parameters are associated with greater AF burden 
in patient with dual-chamber pacemaker. 
 
3. The adverse LA remodelling parameters and AF burden are associated with 
higher level of plasma indices of thrombogenesis in the pacemaker population. 
 
The second part of this thesis will examine the relationship between interatrial 
conduction time and the development of atrial arrhythmia in patients with dual chamber 
pacemakers. 
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This is a case-control observational study. 
 
 
 
2.3 Subject Recruitment 
 
2.3.1 Pacemaker patients 
Patients with dual-chamber pacemaker incorporating advanced AF detection algorithms 
were identified from the pacemaker clinic database, in which all patients with 
pacemaker follow-up were recorded. This population of patients was selected to allow 
assessment of AF burden without the need for prolonged period of ambulatory 
monitoring. Inclusion criteria were patients over the age of 18 with conventional 
indication for dual chamber pacing (sinus node or atrioventricular node disease) and 
device implantation from the year 2005 onwards.  
 
Exclusion criteria included patients with previously documented permanent AF, recent 
device implant (less than 3 months) that need stabilisation of leads and patients with 
pacemaker system dysfunction(eg: atrial over-sensing). Patients with known left 
ventricular ejection fraction of < 40% or clinically significant valvular heart disease, 
malignancy, immune disease, connective tissue disease, untreated thyroid disease, 
chronic liver disease, renal failure (estimated GFR < 30ml/min),pregnancy and those 
who refused consent were also excluded. 
 
2.3.2 Ethical consideration 
The study was conducted in accordance with the declaration of Helsinki. Ethical 
approval has been obtained from national research ethical committee. Approval was 
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also obtained from the research and development (R & D) department of Sandwell and 
West Birmingham NHS Trust. Written consent was obtained from all patients. 
 
2.4 Collection of Data 
 
Following verbal and written informed consent, basic clinical information which 
includes demographics, height, weight, smoking status, alcohol consumption, co-
morbidities and concomitant medications were recorded. All recruited patients also 
underwent detailed physical examinations which include blood pressure measurement 
following a minimum of 10 minutes rest. A 12-lead electrocardiogram (ECG) was also 
performed on all patients. Blood specimens, transthoracic echocardiogram and 
pacemaker interrogation were performed.  
 
 
2.5 Transthoracic Echocardiogram 
 
In all participants, 2 dimensional transthoracic echocardiography (2DE) and real time 
3-dimensional echocardiography (RT3DE) were performed using Phillips iE33 
ultrasound machine (Bothel, WA, USA) in the standard lateral decubitus position.  
Modern off-line QLAB software [Xcelera, Phillip (iE33) Ultrasound Quantification 
Module, USA] was used for quantification of LV systolic/diastolic function and left 
atrial (LA) volume assessment. 
 
2.5.1 Two (2)-Dimensional Transthoracic Echocardiography (2DE) 
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In 2DE, standard resting images of parasternal long axis, short axis, apical 4-chamber, 
apical 5-chamber, apical 2-chamber and apical 3-chamber views were acquired. 
 
Left atrial volumes (LAV) were measured according to the following formula: 
1- Ellipsoid method – π/6 (LxD1xD2), where L was long-axis from apical four-
chamber, D1 was the AP dimension from the parasternal long-axis and D2 was the 
septal-lateral dimension from apical four-chamber view. 
2- Area-length method – 8(A1)(A2)/3π(L), where A1 and A2 were the maximal 
LA area from the apical four-chamber and two-chamber views respectively, and L was 
the LA long-axis length measured from the middle of the plane of the mitral annulus to 
the superior aspect of the LA. The LA long-axis length, L, was measured in both four-
chamber and two-chamber views, and the common length was used in the formula. 
 
Left atrial volume index (LAVi) was calculated by dividing left atrial volume by body 
surface area (square root of the weight x height / 3600). This measurement method is 
more reproducible compared to other methods of LAV [Lang et al 2005]. 
 
Left ventricular systolic function was assessed by the means of left ventricular ejection 
fraction (LVEF), left ventricular end-diastolic volume (LVEDV) and left ventricular 
end-systolic volume (LVESV) by using the modified Simpson’s biplane method 
[Senior et al 1994]. M-mode measurement of LVEF was also measured where 
appropriate. 
 
Left ventricular diastolic function was assessed by different modalities. Transmitral 
flow was obtained in the apical 4-chamber position, where the pulsed Doppler sample 
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volume cursor was placed in parallel with the flow direction. For every parameter, at 
least three samples of flow direction were taken sequentially and the average was 
calculated. Mitral early inflow peak velocity (E), late inflow peak velocity (A), and E 
deceleration time were calculated with conventional Doppler measurement technique. 
Isovolumetric relaxation time (IVRT) was calculated using the pulsed Doppler sample 
placing between aortic and septal annulus of mitral valve in apical five-chamber view. 
Sample volume of pulsed Doppler was located at the base of mitral annulus at the septal 
wall and lateral wall in apical four-chamber view with tissue Doppler imaging (TDI) 
preset activated. Peak early (E’) and late myocardial velocities (A’), myocardial 
systolic wave (S’) on both mitral annular sites were obtained [De Boeck et al. 2003].  
 
2.5.2 Real Time 3-Dimensional Trans-thoracic Echocardiography (RT3DE) 
RT3DE was performed in apical views. Three-dimensional LV and LA images were 
taken by wide-angled acquisition (full-volume method) during end expiration. Off-line 
QLAB software was used for displaying and quantifying 3-dimensional images. The 
LV and LA volume were measured using a semiautomatic tracing of endocardial border 
at systole and diastole at each frame during one cardiac cycle [Anwar and Nosir 
2008].Automatic tracings were manually modified if necessary. Left ventricular and 
LA-diastolic volume, end-systolic volume, ejection fraction and stroke volume (SV) 
were calculated [Anwar and Nosir2008, Poutanen et al. 2003]. LA appendage and 
pulmonary vein aperture were excluded from LA volume calculations. This technique 
was validated in our laboratory, both inter- and intra-observer variability on ten 
individuals was <5%.  
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2.6 Pacemaker Interrogation  
 
In the pacemaker cohort, interrogation of pacemaker was performed at baseline and 12 
months follow-up. The study recruited patients with Vitatron (T series), Medtronic 
(Sensia, Kappa) and St Jude (Integrity) pacemakers. Separate analyses were performed 
based on the pacemaker manufacturer. Standard pacemaker parameter such as sensed 
and paced AV delays and percentage pacing were recorded. Episodes of premature 
atrial contraction (PAC), mode switching, AF burden percentage (calculated by time in 
mode switch form over 1 day interval) and atrial high rate events [(AHREs) defined as 
rate greater than 220 beats per minute and more than 5 minutes duration] were 
recorded. Patients with persistent atrial oversensing were excluded. The diagnostic 
capacity of the devices was used to determine AF burden. The algorithms for AF 
prevention and the device setting were at the Cardiologist discretion.  
 
 
2.7 Laboratory Methods 
 
Venous blood was obtained at baseline (all patients) and follow up visits (only 
pacemaker cohort).  25 millilitre (mls) of blood was drawn from antecubital vein 
following non-traumatic venepuncture into Vacutainer tubes (Becton Dickinson; 
Oxford, England) which contained EDTA, serum and citrates (0.5 ml of 3.8% sodium 
citrate) respectively. 
 
Blood was kept on ice and processed within 60 minutes of sampling. Platelet poor 
plasma fractions will be obtained by centrifugation at 4°C for 20 minutes at 2000 rpm. 
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The resultant supernatant (plasma/serum) was aspirated and aliquoted into individual 
vials. Aliquots will be stored at –70°C for batch analysis by enzyme-linked 
immunosorbent assay (ELISA). All plasma laboratory work was carried out in 
Haemostasis, Thrombosis and Vascular Biology Unit at Birmingham City Hospital. 
 
 
 
2.7.1 ELISA 
Indirect enzyme linked immunosorbent assay (ELISA) was used to measure von 
Willebrand factor (vWf), soluble P-selectin (sPsel), Tissue Factor (TF), D-dimer 
(DDM),  Matrix Metalloproteinase-1 (MMP1) and Tissue Inhibitors of 
Metalloproteinases-1 (TIMP-1). 
 
The principles of ELISA are based on the detection of solubilised antigen in an 
appropriate buffer by primary or capture antibody onto a plastic surface. Serum usually 
needs dilution to 1 in 5 or 1 in 10 in a phosphate buffer solution (PBS). After 
incubation, block and sequential washes with PBS-Tween solution, the bound antigen-
antibody is then exposed to a secondary or detection antibody. Adding in appropriate 
reagents to conjugate with the secondary antibody will lead to colour development. 
This colour is detected at as set wavelength (450 or 490nm) using a spectrophotometer 
which in turn give rise to optical absorbance (OD) for each sample. Each individual OD 
allows for dose calculation of the marker in each individual sample using a graph (log 3 
cycle x linear) of known standards on the same plate and their ODs.  
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vWf was measured by commercially available ELISA (Dako, Glosrup, Denmark). sPsel 
was measured by reagents and recombinant human P-selectin obtained from R&D 
Systems (UK) Ltd (Abingdon, Oxon, UK). TF, TIMP1 and MMP1 were measured by 
commercially available kits from R&D System (UK) Ltd (Abingdon, Oxon, UK).   
 
The intra and inter assay coefficient of variation were measured at <5% and <10% for a 
set of 10 samples. The standard operating procedures of the technique for each 
biomarker are detailed under appendix section. 
 
2.8 Data analysis and Statistics 
 
2.8.1 Power Calculation 
A recent prospective analysis of patients with permanent pacemakers had estimated 
around 24% had documented episodes of AF by 1 year (Cheung et al. 2006). Episodes 
of AF were identified by pacemaker detection algorithms as atrial high rate episodes 
(AHRE) of greater than five minutes duration. We hypothesise that an increasing 
burden of AF correlates to increasing markers of thrombogenesis and LA remodelling. 
Based on these parameters, 100 patients are required to achieve a correlation coefficient 
of 0.4 with a power of 0.8.  
 
2.8.2 Data Analysis 
Categorical variables were expressed as percentage or frequencies and compared using 
Pearson chi-squared test. Continuous variables were subjected to Shapiro-Wilks test to 
determine normal distribution. Normally distributed data was expressed as mean ± 
standard deviation, while non-parametrically distributed data was expressed as median 
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with interquartile range (IQR). For normally distributed continuous variables, a 2-tailed 
analysis of variance (ANOVA) or t-tests (independent or paired) were performed. For 
non-normally distributed variables, a Kruskal-Wallis test was performed to compare 
between groups. Correlations were calculated using the Spearmans rank or Pearson 
method as appropriate. Univariate analyses were first used to identify the relation of 
each echocardiography parameters with pacing data and thrombogenesis markers. All 
variables with a p-value <0.20 were entered into the multivariate model. Multivariate 
analysis was performed by stepwise multiple regression analysis. All p-values were 
quoted to 2 decimal places and a p value of <0.05 will be considered statistically 
significant. All statistical analyses were performed on Minitab 15 package for 
Windows. 
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CHAPTER 3. RESULTS 
 
3.1  THE RELATIONSHIP OF PERCENTAGE PACING WITH CARDIAC 
REMODELLING IN PATIENTS WITH DUAL CHAMBER PACEMAKERS 
 
ABSTRACT 
Background: The implantation of dual-chamber pacemaker has increased significantly 
over the last 2 decades. Cumulative atrial and ventricular pacing are associated with 
adverse cardiac remodelling. We aimed to assess the prevalence of cardiac remodelling 
in relation to percentage pacing. 
Methods: 101 patients (69% men; mean age of 72 ± 11 years) with dual-chamber 
pacemaker underwent two-dimension (2D), real time 3-dimension (3D) and tissue 
Doppler imaging (TDI) echocardiography. LA volume (LAV) was evaluated by area-
length method and 3D method. LA function was assessed by septal A’. Left ventricle 
(LV) systolic and diastolic parameters were evaluated by mitral inflow velocity (E, A), 
LV ejection fraction (biplane Simpson’s) and septal TDI velocity. Pacemaker 
interrogation was performed based on different pacemaker manufacturer. Cohort was 
divided according to low and high percentage pacing. 
Results: The median cumulative percentage atrial pacing (%AP) was 33.2 (IQR 6.2–
85.5) and median cumulative percentage ventricular pacing (%VP) was 40.0 (IQR 3.1–
99.5). Cardiac remodelling parameters were not statistically significant difference 
between patients who had low and high %AP. Patients with higher %VP had 
significantly larger LA volume, reduced longitudinal left ventricular (Septal S) and 
right ventricular functions (TAPSE) (all p<0.05). The %VP had significant correlation 
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with LA volume (r=0.468, p<0.01) and also negatively correlated with Septal S 
(r=0.277, p=0.05). 
Conclusion: Increasing percentage ventricular pacing is associated with enlargement of 
LA and reduces LV as well as RV function. 
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INTRODUCTION 
 
Cardiac pacing is an effective treatment for bradyarrhythmias, as recommended by 
international guidelines [Epstein et al 2008, Vardas et al 2007]. One population study 
showed that the implantation of dual-chamber system increased from 18.6% in 1980-84 
to 71.2% in 2000-2004 on patients who require pacemaker [Uslan et al 2008]. The right 
ventricular (RV) lead is typically placed at the apex due to ease of implantation and 
perceived stability. However, RV apical pacing may have detrimental effects on cardiac 
structure and function (remodelling) [Sweeney and Prinzen 2006], which may be 
related to the abnormal electrical and mechanical activation of the left ventricle (LV). 
 
Cardiac pacing from the RV apex produces a slow depolarisation wave through the 
myocardium instead of specialised conduction tissue. This depolarisation wave is a 
reversal of the intrinsic conduction system which results in depolarising from the apex 
to the base and from the right to the left ventricle [Karpawich and Mital 1997]. This 
abnormal pattern of depolarisation leads to increase activation time (broad QRS 
complex on surface ECG) with delayed activation of the lateral wall of the left ventricle 
(LV) that resembles left bundle branch block [Vassallo et al 1986]. The differences in 
contraction pattern results in redistribution of mechanical work, myocardial strain, 
perfusion pattern and oxygen demand within the LV wall [Baller et al 1988, Delhaas 
1994, Lee et al 1994, Prinzen et al 1990, Prinzen et al 1999]. Various studies have 
shown that dual-chamber pacing tends to have adverse effect on ventricular function 
[Kerr et al 2004, Sweeney et al 2003]. 
51 
 
 
This study evaluated the relationship between the percentages of right ventricular 
pacing with parameter of cardiac remodelling in patients with dual-chamber 
pacemakers. We tested the hypothesis that patients with higher percentage of atrial or 
ventricular pacing would have greater degree of cardiac remodelling. 
 
METHODS 
 
This is a cross-sectional study of patients with dual-chamber pacemaker identified from 
our pacemaker clinic database. Inclusion criteria were patients over the age of 18 with 
appropriately functioning dual chamber pacemakers implanted for sinus node or 
atrioventricular node disease (>3 months post-implant) under active follow-up with our 
pacemaker clinic. 
 
The full methodology and statistical analysis have been covered in Chapter 2. 
 
RESULTS 
 
We recruited 101 patients with dual chamber pacemakers (mean age 72 ± 11 years, 69 
(%) men). Majority of patients had multiple co-morbidities on medical therapy. The 
main indications for dual chamber pacemaker implantation were sinus node and atrio-
ventricular node diseases. (Table 3.1a) Transthoracic echocardiography demonstrated 
mildly impaired left ventricular systolic function, abnormal parameters of diastolic 
function and longitudinal systolic function. Mean LA dimension was within normal 
range, although LA volume was slightly enlarged. (Table 3.1b)  
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Median cumulative percentage atrial pacing (%AP) was 33.2% (IQR 6.2 – 85.5) in the 
study. The patients were subdivided according to the median %AP as low [≤33.2% 
(n=51)] vs high [>33.2% (n=50)]. Patients who had higher %AP had significant 
prolonged interventricular relaxation time (p=0.012), but other LV diastolic and 
systolic function parameters as well as LA parameters were not statistically significant 
between low and high %AP. (Table 3.1c)  
 
Median cumulative percentage ventricular pacing (%VP) was 40.0% (IQR 3.1–99.5). 
Patients were divided according to the median of %VP as low [≤40% (n=51)] vs high 
[>40% (n=50)] (Table 3.1d). Left atrial volume were significantly larger in patients 
who had higher ventricular pacing (p=0.04) but septal A’ on tissue Doppler were 
similar between the 2 patient groups of %VP. Both LV and RV longitudinal function 
were significantly reduced in patients with high %VP but other LV diastolic parameters 
were similar between the groups.  
 
Only %VP had a significant correlation with LA volume (r=0.491, p=0.001). On 
multiple stepwise regression analysis, LA volume remained independently related to 
higher VP (R2=31.1, p<0.001). 
 
When patients with sinus and atrio-ventricular node diseases were compared [Table 
3.1e], the only significant difference was seen with mean age, with atrio-ventricular 
disease patients being older.  Other indices of cardiac remodelling were not 
significantly different. 
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DISCUSSION 
 
In our study, increasing percentage ventricular pacing is associated with enlargement of 
LA and reduced indices of left and right ventricular function. 
 
Our patients were representative of the typical pacemaker population with regards to 
age, co-morbidities and medical therapy. Left ventricular (LV) systolic and diastolic 
functions were mildly impaired in patients with dual-chamber pacemakers. Reversed 
E/A ratio and increased interventricular relaxation time (IVRT) suggested abnormal 
relaxation of the left ventricle, whilst a mean left atrial (LA) volume of more than 50ml 
[Lang et al 2005] reflects the chronicity and severity of the adverse haemodynamics 
within the left ventricle. This observation of LA enlargement (antero-posterior 
dimension) has been shown at other population studies with patients of coronary artery 
disease, hypertension and heart failure [Abhayaratnaet al 2006, Tsang et al 2002, 2003] 
and now with patients with dual-chamber pacemaker in our study. 
 
Nielsen et al. [Nielsen et al 2003] demonstrated the use of dual-chamber pacing is 
associated with left atrial enlargement in relative to atrial pacing. In our study, we 
found no statistically significant differences in left atrial remodelling parameters in 
response to cumulative percentage atrial pacing. LA volume and global function were 
no difference in relation to percentage of atrial pacing. This study further suggests that 
ventricular pacing is the main driver for left atrial remodelling. 
 
Previous studies had demonstrated reduced left ventricular function was associated with 
right ventricular pacing [Lee et al. 1994, Nielsen et al. 2000, 2003, Prinzen and Peschar 
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2002, Rosenqvist et al. 1996, Tse and Lau 1997]. In our study, LV systolic function 
was reduced in the higher cumulative ventricular pacing group and the longitudinal 
functions of both left and right ventricles were also significantly reduced in the group 
with higher %VP. This suggests that impairment of longitudinal function of ventricles 
may precede global systolic impairment. The Mode Selection Trial [Sweeney et al 
2003] and the Dual Chamber and VVI Implantable Defibrillator (DAVID) trial 
[Wilkoff et al. 2002] showed that increased in RV pacing resulted in increased risk of 
mortality and hospitalisation for heart failure. All patients recruited has dual chamber 
pacing, thus has minimal atrio-ventricular dyssynchrony. However, RV pacing, which 
promotes ventricular dyssynchrony and worsening of mitral regurgitation could explain 
the deterioration in LV systolic function. The worsening of LV systolic function in turn 
gives rise to higher filling pressure within the LV. This observation is consistent with a 
relatively high E/E’ in our study (suggestive of elevated left ventricular filling 
pressure). The change in LV function and mitral regurgitation may explain the 
association between RV pacing and LA dilatation. 
 
LIMITATIONS 
 
This study is limited by the relatively small sample size and our cohort of patients with 
mixed co-morbidities which may well affect the various parameters of cardiac 
remodelling. However, this reflect a ‘real life’ situation when study elderly cohort who 
often have other co-morbidities. Although our result suggests that impairment of 
longitudinal function of ventricles may precede the development of global ventricle 
dysfunction, future large prospective studies with a longitudinal component are 
warranted to prove this concept. 
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CONCLUSION 
 
In our study, we demonstrate no clear association between percentages of atrial pacing 
with cardiac remodelling. However, increased ventricular pacing is associated with left 
atrial enlargement and reduced left and right ventricles global function.  
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Table 3.1a Demographic characteristics of study population 
 N = 101 
Demographic 
   Age (years) 
   Gender (Male) 
   Ethnicity (Cauc; Afro-Carr; Asian) 
   Height (cm) 
   Weight (kg) 
   Body Mass Index (kg/m2) 
   Body Surface Area (m2) 
   Heart Rate ( per min) 
   Systolic Blood Pressure (mmHg) 
   Diastolic Blood Pressure (mmHg) 
   Smoker (Never; Ex; Current) 
   Alcohol (>10 units/week) 
 
72 ±11 
69 / 101 
72;12;17 
169 ± 90 
76 ± 16 
26.6 ± 4.3 
1.88 ± 0.23 
73 ± 9 
138 ± 22 
77±11 
47;12; 41 
65 / 101 
Indication for pacing 
   Sinus node disease 
   Atrioventricular node disease 
 
40 / 101 
61 / 101 
Co-morbidities 
   Hypertension 
   Diabetes 
   Ischaemic Heart Disease 
   Valvular Heart Disease 
   Stroke / TIA  
   Hyperlipidaemia 
   Peripheral Vascular Disease 
   NYHA Class 1 
   NYHA Class 2 
   NYHA Class 3 
 
67 / 101 
20 / 101 
39 / 101 
8 / 101 
10 / 101 
70 / 101 
6 / 101 
65 / 101 
35 / 101 
1 / 101 
Current medications 
ACEi / ARBs 
   Beta-blocker  
   Calcium channel blocker 
   Diuretics 
   Antiplatelet Agents 
   Warfarin 
   Statin 
 
61 / 101 
31 /101 
32 / 101 
35 / 101 
74 / 101 
14 / 101 
65 / 101 
 
Cauc=Caucasion; Afro-Carr=Afro-Caribbean; ACEi=Angiotensin Converting Enzyme 
Inhibitor; ARBs=Angiotensin Receptors Blockers; NYHA=New York Heart Association 
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Table 3.1b Echocardiographic parameters of pacemaker cohort 
 Mean ± SD 
Left Atrial (LA) Remodelling 
   LA Dimension, cm 
   LA Volume (AL), ml 
   LA Volume (3D), ml  
   Index AL, ml/m2 
   Index 3D, ml/m2 
   Septal A’, cm/s 
   Lateral A’, cm/s 
 
4.0 ± 0.7 
52.7 ± 16.4 
55.2 ± 14.2 
28.2 ± 8.4 
29.8 ± 7.4 
8.5 ± 2.5 
9.9 ± 3.1 
Left Ventricle (LV) Measurements 
   Ejection Fraction (Simpson), % 
   Early inflow peak velocity (E), cm/s 
   Late inflow peak velocity (A), cm/s 
   E/A 
   IVRT, ms 
   Septal E’, cm/s  
   Septal E/E’ 
   MAPSE, cm 
   Septal S, cm/s 
   Lateral S, cm/s 
 
52.7 ± 11.9 
69.2 ± 20.7 
84.9 ± 23.3 
0.8 (0.6 – 0.9)  
108.7 ± 21.2 
5.4 ± 1.8 
14.1 ± 6.4 
1.5 ± 0.3 
6.5 ± 1.7 
8.0 ± 2.4 
Right Ventricle Measurement 
   TAPSE, cm 
 
2.3 ± 0.5 
 
AL=area-length method; 3D=3 dimensional; E/A=ratio between early and late inflow 
peak velocity; IVRT=interventricular relaxation time; E’=peak early myocardial 
velocity; A’=late myocardial velocity; S= myocardial systolic wave; E/E’=ratio 
between early inflow peak velocity with peak early myocardial velocity; MAPSE= 
mitral annular plane of systolic excursion; TAPSE=tricuspid annular plane of systolic 
excursion  
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Table 3.1c Relationship of percentage atrial pacing with cardiac remodelling 
 
Variables AP ≤ 33.2%  
(n=51) 
AP > 33.2%   
(n=50) 
p value 
Demographics 
   Age,years 
   Height, cm 
   Weight, kg 
   BMI,  kg/m2 
   BSA 
   HR (per min) 
   SBP, mmHg 
   DBP, mmHg 
 
70.4 ± 11.0 
169.0 ± 8.0 
77.8 ± 10.8 
27.0 ± 3.1 
1.9 ± 0.6 
74.4 ± 9.9 
136.0 ± 21.0 
76.0 ± 11.0 
 
73.5 ± 10.0 
169.0 ± 10.0 
77.3 ± 19.3 
26.9 ± 4.9 
1.9 ± 0.3  
72.3 ±  9.0 
141.0 ± 22.0 
71.0 ± 10.0 
 
0.17 
0.81 
0.88 
0.85 
0.73 
0.29 
0.31 
0.22 
 Co-morbidities 
   Hypertension 
   Diabetes 
   Ischaemic Heart Disease 
   Stroke 
 
33 / 51 
37 / 51 
21 / 51 
7 / 51 
 
31 / 50 
39 / 50 
18 / 50 
3 / 50 
 
 Left Atrial (LA) Remodelling 
   LA Dimension, cm 
   LA Volume (AL), ml 
   Index AL, ml/m2 
   Septal A’, cm/s 
 
4.0 ± 0.6 
52.9 ± 12.5 
27.9 ± 10.0 
8.3 ± 3.4 
 
4.1 ± 0.8 
53.5 ± 20.1 
28.4 ± 6.8 
8.3 ±2.6 
 
0.87 
0.88 
0.78 
0.94 
Left Ventricle (LV) Measurements 
   Ejection Fraction (Simpson), % 
   Early inflow peak velocity (E), cm/s 
   Late inflow peak velocity (A), cm/s 
   E/A 
   IVRT, ms 
   Septal E’, cm/s  
   Septal E/E’  
   MAPSE, cm 
   Septal S, cm/s 
 
52 ± 11.5 
72.4 ± 19.9 
84.2 ± 22.3 
0.8 (0.6 – 1.0)  
103.3 ± 20.2 
5.5 ± 1.9 
14.6 ± 6.8 
1.4 ± 0.4 
6.5 ± 1.8 
 
53.2 ± 12.9 
66.9 ± 21.9 
86.6 ± 19.6 
0.7 (0.6 – 0.8)  
114.3 ± 21.0 
5.0 ± 1.4 
14.1 ± 6.1 
1.5 ± 0.3 
6.3 ±1.6 
 
0.65 
0.20 
0.22 
0.07 
0.01 
0.14 
0.74 
0.66 
0.60 
Right Ventricle Measurement 
   TAPSE, cm 
 
2.3 ± 0.5 
 
2.4 ± 0.6 
 
0.39 
 
BMI=body mass index; BSA=body surface area; HR=heart rate; SBP=systolic blood 
pressure; DBP=diastolic blood pressure; AL=area-length method; 3D=3 dimensional; 
E/A=ratio between early and late inflow peak velocity; IVRT=interventricular 
relaxation time; E’=peak early myocardial velocity; A’=late myocardial velocity; S= 
myocardial systolic wave; E/E’=ratio between early inflow peak velocity with peak 
early myocardial velocity; MAPSE= mitral annular plane of systolic excursion; 
TAPSE=tricuspid annular plane of systolic excursion 
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Table 3.1d Relationship of percentage ventricular pacing with cardiac remodelling 
 
Variables VP ≤ 40%  (n=51) VP > 40%   (n=50) p value 
Demographics 
   Age, years 
   Height. cm 
   Weight, kg 
   BMI, kg/m2 
   BSA 
   HR (per min) 
   SBP, mmHg 
   DBP, mmHg 
 
70.0 ± 12.1 
168.9 ± 9.1 
74.2 ± 16.1 
25.8 ± 4.0 
1.9 ± 0.2 
72.4 ± 8.6 
135.9 ± 23.7 
75.6 ± 11.1 
 
74.1 ± 8.9 
169.0 ± 9.1 
78.4 ± 16.0 
27.4 ± 4.6 
1.9 ± 0.2  
74.0 ±  9.9 
140.6 ± 21.0 
78.9 ± 10.7 
 
0.06 
0.96 
0.18 
0.07 
0.26 
0.39 
0.30 
0.14 
Co-morbidities 
   Hypertension 
   Diabetes 
   Ischaemic Heart Disease 
   Stroke 
   NYHA Class 1 
   NYHA Class 2 
   ACEi / ARB 
   Beta blockers 
   Calcium Antagonist 
   Antiplatelets 
   Oral anticoagulant 
   Diuretics 
   Statins 
 
30 / 51 
7 / 51 
22 / 51 
2 / 51 
21 / 51 
14 / 51 
27 / 51 
15 / 51 
13 / 51 
35 / 51 
5 / 51 
15 / 51 
28 / 51 
 
37 / 50 
13 / 50 
17 / 50 
8 / 50 
19 / 50 
22 / 50 
33 / 50 
16 / 50 
19 / 50 
35 / 50 
9 / 50 
20 / 50 
37 / 50 
 
Left Atrial (LA) Remodelling 
   LA Dimension, cm 
   LA Volume (AL), ml 
   Index AL, ml/m2 
   Septal A’, cm/s 
   Lateral A’, cm/s 
 
4.0 ± 0.8 
51.6 ± 17.2 
28.5 ± 9.3 
8.5 ± 1.9 
10.1 ± 2.5 
 
4.2 ± 0.6 
59.5 ± 17.9 
31.1 ± 9.4 
8.2 ±2.9 
9.7 ± 3.6 
 
0.17 
0.04 
0.20 
0.58 
0.52 
Left Ventricle (LV) Measurements 
   Ejection Fraction (Simpson), % 
   Early inflow peak velocity (E), cm/s 
   Late inflow peak velocity (A), cm/s 
   E/A 
   IVRT, ms 
   Deceleration Time, ms 
   Septal E’, cm/s 
   Lateral E’, cm/s  
   Septal E/E’  
   MAPSE, cm 
   Septal S, cm/s 
   Lateral S, cm/s 
 
54.0 ± 12.1 
68.5 ± 21.5 
82.7 ± 21.7 
0.79 (0.67 – 0.92)  
106.1 ± 20.7 
259.2 ± 66.8 
5.5 ± 1.9 
7.5 ± 2.8 
13.8 ± 7.0 
1.5 ± 0.3 
6.8 ± 1.8 
8.2 ± 2.4 
 
51.2 ± 11.6 
69.9 ± 19.9 
87.2 ± 24.9 
0.74 (0.63 – 0.83)  
111.4 ± 21.3 
248.6 ± 84.3 
5.2 ± 1.6 
6.5 ± 2.5 
14.4 ± 5.7 
1.4 ± 0.3 
6.1 ±1.5 
7.8 ± 2.4 
 
0.24 
0.73 
0.35 
0.15 
0.21 
0.49 
0.34 
0.08 
0.62 
0.36 
0.04 
0.44 
Right Ventricle Measurement 
   TAPSE, cm 
 
2.4 ± 0.5 
 
2.2 ± 0.5 
 
0.04 
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BMI=body mass index; BSA=body surface area; HR=heart rate; SBP=systolic blood 
pressure; DBP=diastolic blood pressure; PVD=peripheral vascular disease; 
NYHA=New York Heart Association; ACEi=angiotensin converting enzyme inhibitor; 
ARB=angiotensin receptor blocker; AL=area-length method; E/A=ratio between early 
and late inflow peak velocity; IVRT=interventricular relaxation time; E’=peak early 
myocardial velocity; A’=late myocardial velocity; S= myocardial systolic wave; 
E/E’=ratio between early inflow peak velocity with peak early myocardial velocity; 
MAPSE= mitral annular plane of systolic excursion; TAPSE=tricuspid annular plane 
of systolic excursion 
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Table 3.1e Cardiac remodelling in patients with sinus and atrio-ventricular node 
diseases 
Variables Sinus node   
(n=40) 
Atrio-ventricular 
node   (n=61) 
p value 
Demographics 
   Age, years 
   Height, cm 
   Weight, kg 
   BMI, kg/m2 
   BSA 
   HR (per min) 
   SBP, mmHg 
   DBP, mmHg 
 
68.5 ± 12.5 
170.2 ± 8.6 
77.4 ± 18.6 
26.6 ± 5.1 
1.9 ± 0.3 
73.7 ± 8.1 
132.8 ± 24.4 
75.5 ± 12.0 
 
74.4 ± 8.8 
168.1 ± 9.4 
75.5 ± 14.4 
26.6 ± 3.8 
1.9 ± 0.2  
72.8 ±  10.0 
141.7 ± 20.4 
78.3 ± 10.1 
 
0.01 
0.24 
0.58 
0.96 
0.50 
0.61 
0.06 
0.23 
Co-morbidities 
   Hypertension 
   Diabetes 
   Ischaemic Heart Disease 
   Stroke 
   NYHA Class 1 
   NYHA Class 2 
   ACEi / ARB 
   Beta blockers 
   Calcium Antagonist 
   Antiplatelets 
   Oral anticoagulant 
   Diuretics 
   Statins 
 
24 / 40 
4 / 40 
19 / 40 
1 / 40 
16 / 40 
12 / 40 
23 / 40 
11 / 40 
11 / 40 
27 / 40 
5 / 40 
12/ 40 
23 / 40 
 
43 / 61 
16 / 61 
20 / 61 
9 / 61 
24 / 61 
24 / 61 
37 / 61 
20 / 61 
21 / 61 
43 / 61 
9 / 61 
23 / 61 
42 / 61 
 
Left Atrial (LA) Remodelling 
   LA Dimension, cm 
   LA Volume (AL), ml 
   Index AL, ml/m2 
   Septal A’, cm/s 
   Lateral A’, cm/s 
 
4.0 ± 0.8 
52.8 ± 18.1 
28.5 ± 9.2 
8.4 ± 2.2 
9.7 ± 2.4 
 
4.1 ± 0.7 
57.1 ± 17.7 
30.1 ± 9.5 
8.4 ±2.7 
10.0 ± 3.5 
 
0.65 
0.29 
0.31 
0.90 
0.59 
Left Ventricle (LV) Measurements  
   Ejection Fraction (Simpson), % 
 
52.8 ± 13.0 
 
52.6 ± 11.1 
 
0.95 
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   Early inflow peak velocity (E), cm/s 
   Late inflow peak velocity (A), cm/s 
   E/A 
   IVRT, ms 
   Deceleration Time, ms 
   Septal E’, cm/s 
   Lateral E’, cm/s  
   Septal E/E’  
   Lateral E/E’ 
   MAPSE, cm 
   Septal S, cm/s 
   Lateral S, cm/s 
70.1 ± 20.2 
82.6 ± 20.2 
0.85 (0.69 – 0.95)  
104.3 ± 19.9 
269.8 ± 67.0 
5.8 ± 1.9 
8.1 ± 2.8 
13.4 ± 5.8 
9.5 ± 3.9 
1.5 ± 0.3 
7.1 ± 1.8 
8.4 ± 2.7 
68.6 ± 21.1 
86.4 ± 25.2 
0.74 (0.63 – 0.82)  
111.7 ± 21.5 
243.5 ± 79.7 
5.1 ± 1.6 
6.4 ± 2.4 
14.6 ± 6.7 
12.2 ± 6.4 
1.4 ± 0.3 
6.1 ±1.5 
7.7 ± 2.3 
0.72 
0.40 
0.61 
0.08 
0.08 
0.05 
0.01 
0.36 
0.02 
0.25 
0.01 
0.27 
Right Ventricle Measurement 
   TAPSE, cm 
 
2.4 ± 0.5 
 
2.2 ± 0.5 
 
0.10 
 
BMI=body mass index; BSA=body surface area; HR=heart rate; SBP=systolic blood 
pressure; DBP=diastolic blood pressure; PVD=peripheral vascular disease; 
NYHA=New York Heart Association; ACEi=angiotensin converting enzyme inhibitor; 
ARB=angiotensin receptor blocker; AL=area-length method; E/A=ratio between early 
and late inflow peak velocity; IVRT=interventricular relaxation time; E’=peak early 
myocardial velocity; A’=late myocardial velocity; S= myocardial systolic wave; 
E/E’=ratio between early inflow peak velocity with peak early myocardial velocity; 
MAPSE= mitral annular plane of systolic excursion; TAPSE=tricuspid annular plane 
of systolic excursion 
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3.2 THE RELATIONSHIPS OF LEFT ATRIAL REMODELLING WITH 
ATRIAL HIGH RATE EPISODES AND THROMBOGENESIS IN 
PACEMAKER POPULATION 
 
ABSTRACT 
Background: Cumulative ventricular pacing (VP) is associated with development of 
atrial fibrillation and cardiac remodelling. Contemporary pacemaker device are able to 
quantify atrial high-rate episodes (AHREs) and atrial fibrillation burden (AFB). We 
tested the hypothesised that reverse LA remodelling parameters are associated with 
greater AF burden, higher level of plasma indices of extracellular matrix turnover and 
thrombogenesis, as well as a larger percentage of cumulative ventricular pacing in a 
pacemaker population.  
Methods: We studied 101 patients with dual-chamber pacemaker at baseline and follow 
up at 12 months. AHREs were defined as atrial-rate ≥ 220 beats/min for ≥ 5 minutes. 
AFB and percentage of cumulative pacing were derived from pacemaker diagnostics. 
All patients underwent two-dimension (2D) and tissue Doppler imaging (TDI) 
echocardiography. Plasma markers of extracellular matrix turnover [matrix 
metalloproteinases-1 (MMP1) and tissue inhibitors of metalloproteinases-1 (TIMP1)] 
and thrombogenesis [von Willebrand factor (vWf), tissue factor (TF), soluble P-selectin 
(P-sel) and D-dimer (DDM)] were analysed by enzyme-linked immunosorbent assay 
(ELISA). 
Results: At baseline, patients with AHREs had significantly larger LAV (p=0.008) and 
higher cumulative percentage ventricular pacing (p=0.012). The AFB ranged from 0 – 
99% and correlated with P-sel (r=0.795, p<0.001), DDM (r=0.643, p=0.045), E/A 
(R=0.966, p<0.001), and inversely correlated with septal A’ (R=0.766, p<0.001). On 
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linear regression analysis, P-sel and DDM (P<0.05) along with A, E/A, septal A’ (all 
p<0.01) were independently associated with AFB.  
At 12 months follow up, global LA function and RV longitudinal function were 
reduced significantly (p<0.05). Reverse LA remodelling correlated well with other LV 
diastolic parameters, LV and RV longitudinal function (all p<0.05). Global LA function 
was an independent predictor of LA volume (OR 6.14, P<0.001). The incidence of 
AHREs was 35% with a median percentage AF burden of 2.6 (IQR 0.1 – 26.4) at 
follow up. Patients with AHREs had significantly larger LA volume (p=0.014) and 
reduced LA function at follow up (p=0.034). Stepwise regression analysis demonstrated 
that percentage AP (OR 2.28, p=0.032) and E/A ratio (OR 4.14, P<0.01) were 
predictive of greater AF burden.  Reduced MMP1, and increased TIMP1, P-selectin and 
D-dimer were seen at follow up (p<0.05).   
Conclusion: LA volume enlargement was associated with percentage cumulative atrial 
pacing. Cumulative ventricular pacing and increased LAV are associated with the 
development of AHRE, but AFB is independently associated with changes in LA 
function, LV diastolic function and indices of platelet activation and thrombosis. Global 
LA function was associated with LV longitudinal and diastolic function and is a strong 
predictor of LA volume. LV diastolic function, global LA function and AF burden are 
strong predictors of reverse LA remodelling in patients experienced AHREs. 
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INTRODUCTION 
 
The left atrium (LA) is structurally and functionally linked to the left ventricle (LV). 
Functionally, the LA has been described as a reservoir during LV systole, a conduit 
during early diastole and actively contract during late diastole to aid ventricular filling. 
Hence, the LA is estimated to contribute about 15 to 30% of the LV filling volume 
during the active phase [Spencer et al. 2001].  
 
Structurally, the LA typically undergoes dilatation on prolonged exposure to increased 
haemodynamic load. Hence, an increased LA size (LA remodelling) has been 
consistently reported in patients with hypertension and patients with heart failure 
(regardless of ejection fraction) [Abhayaratnaet al. 2006, Takemoto et al. 2005, Tsang 
et al. 2002, Tsang et al. 2003]. Increase Early inflow peak velocity (E), LA dimension 
either by anteroposterior (AP) diameter or volume has been associated with the 
development of AF [Vaziri et al. 1994, Psaty et al. 1997, Tsang et al. 2001, Tanabe et 
al. 2007, Fatema et al. 2009].   
 
Contemporary pacemaker and other implantable cardiac rhythm devices that 
incorporate an atrial lead allow the storage of atrial high-rate episodes (AHRE), and 
characterisation of atrial fibrillation (AF) recurrences. However, the accuracy of 
device-detected AHRE for AF is dependent on several factors, including the rate and 
duration of the episodes [Nowak et al. 2001, Purerfellner et al. 2004, Passman et al. 
2004]. Pollak et al. [2001] showed that the detection of AHRE correlates well with 
ECG documentation of AF, especially if higher atrial rates of >250 beats/min and 
episodes of longer duration (>5 minutes) are used. AF burden is usually expressed as 
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percentage of time spent in AHRE over a day period. Most manufacturers utilise the 
‘mode-switching’ characteristics of the devices to account for AF burden. Thus, device-
detected AHREs, when appropriately defined, may be reliable estimates of AF 
episodes. 
 
The incidence of AHRE has been variably reported from 24% to 88% [Gillis et al. 
2002, Cheung et al. 2006, Orlov et al. 2007]. Patients with pre-existing AF tend to have 
higher frequency of AHRE and greater AF burden. Most AHRE are asymptomatic 
[Cheung et al. 2006] but are associated with the development of ischaemic stroke, 
embolic events and mortality [Borleffs et al. 2009, Capucci et al. 2005, Glotzer et al. 
2003, Glotzer et al. 2009].  
 
Thrombogenesis in AF has been related to abnormal surrogate markers of coagulation, 
fibrin turnover, endothelial damage/dysfunction and platelets [Watson et al. 2009, 
Becker 2005].  No previous study has investigated the relationship of LA remodelling, 
AHRE and markers of extracellular matrix turnover and thrombogenesis. 
 
The aim of this 12-month prospective study was to correlate changes in LA remodelling 
with the development of AHREs, changes in markers of extracellular matrix turnover 
and thrombogenesis, and relationship with the frequency of (percentage time) 
ventricular pacing in patients with dual-chamber pacemakers. I tested the hypothesis 
that LA remodelling parameters are associated with greater AF burden, higher levels of 
markers extracellular matrix turnover and thrombogenesis, as well as a greater 
percentage of ventricular pacing in a pacemaker population.  
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METHODS 
 
The full methodology and statistical analysis have been covered in Chapter 2. 
 
RESULTS 
We recruited 101 patients with dual chamber pacemakers (mean age 72 ± 11 years, 69 
(%) men) (Previously reported in chapter 3.1, Table 3.1a). Baseline characteristics and 
co-morbidities were comparable between groups with and without AHRE. [Table 3.2a] 
Patients with AHREs had significantly larger LAV (p=0.008) and higher cumulative 
percentage ventricular pacing (p=0.012), whilst cumulative AP between the groups was 
similar. There were no significant differences in LV systolic and diastolic parameters as 
well as thrombogenesis markers between patients with and without AHREs.  
 
AFB ranged from 0 – 99% in the AHRE group, with median of 1.70% (IQR 0.10 – 
10.25) at baseline. Patients with higher AFB had significantly higher body mass index 
(p<0.001) and reduced global LA function (p=0.006). [Table 3.2b] There were no 
significant differences in other parameters of LV systolic and diastolic function as well 
as thrombogenesis markers. AFB correlated with P-sel (r=0.795, p<0.001), DDM 
(r=0.643, p=0.045), E/A (r=0.966, p<0.001), and inversely correlated with septal A’ 
(r=0.766, p<0.001) [Figures 3.2a, 3.2b, 3.2c, 3.2d]. On linear regression analysis, P-sel 
and DDM (P<0.05), E/A ratio and septal A’ (all p<0.01) were independently associated 
with AFB.  
 
Follow up 
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There was a dropout rate of 10% with only 90 patients returning for the follow up visit 
with a median of 364.50 (IQR 302.75 – 402.22) days. Out of the 11 patients who 
dropped out, 2 had died, 1 patient had a cerebral event and 8 patients did not attend 
despite 3 separate appointments. (Figure 3.2e) 
 
The percentage of atrial and ventricular pacing, LA volume and LV systolic function 
were comparable between baseline and 12 months follow up. Diastolic function as 
measured by E/A ratio increased significantly along with prolongation of IVRT 
interval. RV systolic function and global LA function were also significantly reduced at 
1 year follow up. There was a significant increased in TIMP1 levels, and reduced 
MMP1. Biomarkers of thrombogenesis also increased significantly at follow-up. (Table 
3.2c)  
 
Correlations and multiple regression analysis 
Indexed LA volume had moderate correlation with left ventricle diastolic function (E/A 
ratio, r=0.451, p<0.001 and septal E/E’ r=0.379, p<0.001). Also, it was negatively 
correlated with longitudinal left ventricle systolic function (septal S, r=0.446, p<0.001) 
and global LA function (septal A’, r=0.600, p<0.001). The correlation between indexed 
LA volume and percentage pacing was weak (percentage AP, r=0.219, p<0.05; 
percentage VP, r=0.194, p=0.068). Besides, indexed LA volume also correlated with 
TIMP1 (r=0.395, p<0.001). On linear regression analysis, only Septal A’ (p=0.001) and 
percentage AP (p=0.018) remained independently associated with indexed LA volume, 
with R-square of 36.4%. Baseline LA volume (OR 0.85, 95%CI 0.77-0.93, p=0.001) 
and percentage A pace (OR 1.02, 95%CI 1.00-1.04, p=0.014) were both predictive of 
changes of LA volume during follow up. 
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Global LA function as measured by Sep A’ had significant negative correlation with 
LV diastolic function (E/A, r=0.420 and septal E/E’ r=0.436, both p<0.001), indexed 
LA volume (r=0.600, p<0.001) and matrix turnover markers (MMP1, r=0.238, p=0.04; 
TIMP1, r=0.358, p0.001). Besides, LA function also had significant correlations with 
LV and RV longitudinal function (Sep S, r=0.605, p<0.001; TAPSE, r=0.224, 
p=0.043). Correlations with percentage VP were also significant (r=-0.309, p=0.003). 
but only E/A (p=0.023) and Sep S (p=0.004) remained statistically significant on linear 
regression analysis. 
 
Subgroup analysis of patients with AHREs 
Thirty-five patients developed AHREs with median AF burden of 2.6 (IQR 0.1 – 
26.4)%. In this subgroup of patients with AHREs, LA volume was significantly 
enlarged with reduced LA function at 12 months follow up. There were significant 
changes in LV diastolic parameters, LV and RV longitudinal systolic functions as well 
as indices of extracellular matrix turnover and thrombogenesis at follow up. (Table 
3.2d) 
 
There were moderate correlation between AF burden and indexed LA volume, Septal 
A’, E/A ratio, MAPSE, TAPSE and Septal S. (Table 3.2e) Stepwise regression analysis 
demonstrated that percentage Septal A’ (p=0.019) and E/A ratio (P=0.001) were 
strongly predictive of greater AF burden. 
 
Correlation of changes in LA volume and echocardiographic parameters of LA 
function, diastolic function, pacing percentage and biomarkers is summarised in Table 
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3.2f. On linear regression analysis, left ventricular diastolic function (E/A, p=0.027), 
global LA function (Sep A’, p=0.021), AF burden (p=0.023) and extracellular matrix 
turnover (TIMP 1, p= 0.017) remained statistically significant in predicting changes in 
LA volume. 
 
 
DISCUSSION 
This is the first prospective study to investigate the relationship of LA remodelling in 
response to AHRE and indices of extracellular matrix turnover and thrombogenesis in a 
pacemaker population. The main findings are as follows: (i) LA volume enlargement 
was associated with percentage cumulative atrial pacing, (ii) global LA function is 
associated with LV longitudinal and diastolic function and a strong predictor of LA 
volume, and (iii) LV diastolic function, global LA function and AF burden are strong 
predictors of LA remodelling in patients with AHREs. 
 
Several studies of patients with pacemakers have reported that long term ventricular 
pacing caused atrial electrical remodelling, increased atrial dimensions as well as 
induces LV dyssynchrony and dysfunction [Nielsen et al. 1998, Sparks et al. 1999, 
Tops et al. 2009].In my study, although the cumulative ventricular pacing increased 
with follow up, its effect on reverse LA remodelling was not significant. Indeed, it was 
the percentage cumulative atrial pacing that was associated more with LA enlargement. 
It is well known that pacing of the RA appendage significantly worsen the inter-atrial 
conduction and mechanical delay [Ausubel et al. 1986, Hermida et al. 2003, Liang et al. 
2010]. Thus, it is possible that RA pacing induces atrial dyssynchrony and give rise to 
reverse LA remodelling.  
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The left atrium is not only a passive conduit for blood, but also contributes actively to 
ventricular filling. Accurate measurement of LA volume involves clear tracings of the 
endocardial border [Lang et al. 2005]. My study demonstrates that global LA function 
is associated with LV diastolic parameters and longitudinal function as well as a major 
predictor for LA volume. Thus, TDI measurement of global LA function would be a 
reliable and simpler method to predict reverse LA remodelling.  
 
The incidence of AHRE in my study was 35%, which is very similar to several studies 
which have reported the incidence of AHRE to be near 30% in patients without 
histories of AF [Cheung et al. 2006, Schubert et al. 2005]. A novel finding in my study 
is the demonstration of significant reverse LA remodelling (increased LA volume and 
decreased global LA function) and decreased LV and RV longitudinal function in 
patients with AHREs despite similar cumulative atrial and ventricular pacing. The 
increased AF burden was also found to be strongly associated with reverse LA 
remodelling. Cumulative AP and diastolic parameter were also strongly predictive of 
AF burden. The potential explanation for this would be cumulative AP induces 
mechanical dyssynchrony which give rise to reverse LA remodelling. These structural 
and functional changes within the LA predispose individual to develop AHREs and 
thus increase AF burden.  
 
In my study, I demonstrated a down regulated MMP1 and up regulated TIMP1. 
Although this is in contrary to previous studies [Nakano et al. 2004, Zhu et al. 2005], it 
still suggests a pivotal role of the MMP/TIMP system in regulating the process of atrial 
remodelling. Levels of P-selectin and D-dimer also increased significantly between 
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follow up and baseline studies. However, I am not able to identify a clear relationship 
between levels of biomarkers and presence of AF burden. In our study, the level of D-
dimer showed a significant negative correlation with LV systolic function. The general 
lack of correlation between thrombogenesis markers and other clinical characteristics of 
patients as well as echocardiography parameters is rather surprising.    
 
This study has several limitations. First, this is a small pilot study. Second, the follow-
up was not complete. Third, there are currently no reliable method to identify patient 
who might have asymptomatic and silent AF prior to pacemaker implantation and 
subsequently being recruited into my study. Finally, as it is a small study and we do not 
have clinical outcome data, the clinical significance of AHREs cannot be determined at 
this stage.  
 
In conclusion, my study is the first prospective to look into the relationship of reverse 
LA remodelling in response to atrial high rate episodes and thrombogenesis markers in 
pacemaker population. Further studies are needed to understand the relation between 
device implantation, atrial lead placement on the development of AHREs and reverse 
LA remodelling.  
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Figure 3.2a Correlation of AF burden and diastolic function 
 
 
Figure 3.2b Correlation of AF burden and global LA function 
 
 
Figure 3.2c Correlation of AF burden and platelet activation 
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Figure 3.2d Correlation of AF burden and thrombosis 
 
 
 
 
 
 
Figure 3.2e Flow chart of recruitment and follow-up 
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Table 3.2a AHRE in association with cardiac remodelling and thrombogenesis 
markers 
Variables No AHRE (n= 84) AHRE (n=17) P value 
Demographics 
   Age (years) 
   Male, (%) 
   BMI (m2/kg)    
   SBP (mmHg) 
 
71.0 ± 11.6 
58, (69) 
26.4 ± 4.4 
137.8 ± 23.5 
 
75.4 ± 8.8 
13, (76) 
27.6 ± 4.7 
143.2 ± 17.1 
 
0.10 
0.52 
0.38 
0.30 
Co-morbidities 
   Hypertension, (%) 
   Ischaemic heart disease, (%) 
   Antiplatelet, (%) 
 
45, (54) 
34, (40) 
64, (76) 
 
12, (71) 
4, (24) 
14, (82) 
 
0.12 
0.19 
0.74 
Pacing indication 
   Sinus node disease 
   Atrioventricular node disease 
 
46 / 70 
38 / 70 
 
10 / 17 
7 / 10 
 
Cumulative % pacing 
   Atrial pacing, % 
   Ventricular pacing, % 
 
34.6 (6.8 – 81.5)  
21.9 (1.8 – 99.0) 
 
22.1 (6.9 – 65.0)  
98.6 (41.0 – 99.9 ) 
 
0.41 
0.01 
Left Atrial (LA) Remodelling 
   LA Dimension, cm 
   LA Volume (AL), ml 
   Index AL, ml/m2 
   Septal A’, cm/s 
 
4.0 ± 0.7 
51.3 ± 15.5 
27.4 ± 7.9 
8.9 ± 2.2 
 
4.2 ± 0.6 
64.8 ± 16.2 
34.8 ± 9.4 
7.9 ± 2.6 
 
0.27 
0.01 
0.01 
0.16 
Left Ventricle Systolic 
   Ejection Fraction (Simpson), % 
   Septal S, cm/s 
 
52.8 ± 11.9 
6.6 ± 1.8 
 
55.1 ± 9.2 
6.5 ± 1.4 
 
0.40 
0.71 
Left Ventricle Diastolic 
   E/A 
   IVRT, ms 
   Septal E’, cm/s  
   Septal E/E’  
 
0.8 ± 0.3 
109.1 ± 22.1  
5.3 ± 1.7 
13.7 ± 6.2 
 
1.0 ± 0.6 
109.6 ± 15.7 
5.6 ± 1.2 
14.1 ± 3.5 
 
0.23 
0.90 
0.38 
0.74 
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Matrix Turnover Markers 
   MMP 1 (ng/ml) 
   TIMP 1 (ng/ml) 
 
1.2 (0.7 – 2.4) 
1.5 (1.2 – 1.9) 
 
1.3 (1.0 – 2.0) 
1.8 (1.2 – 1.9) 
 
0.75 
0.71 
Thrombogenesis markers 
   vWf, IU/dl 
   TF, ng/ml 
   P-sel, ng/ml 
   DDM, ng/ml 
 
94.2 ± 16.2 
0.2 (0.1 – 0.3)  
47.6 ± 15.8 
180.0 (82.0 – 390.0) 
 
93.9 ± 33.7 
0.1 (0.0 – 0.2)  
63.4 ± 29.7 
152.5 (82.5 – 307.5) 
 
0.98 
0.11 
0.06 
0.55 
 
BMI=body mass index; SBP=systolic blood pressure; AL=area-length method; 
IVRT=interventricular relaxation time; MMP 1= Matrix Metalloproteinase 1; TIMP 
1= Tissue Inhibitors of Metalloproteinase -1; vWf= Von Willebrand Factor; TF=Tissue 
Factor; P-sel=P selectin; DDM=D Dimer 
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Table 3.2b AF burden in association with cardiac remodelling and thrombogenesis 
markers 
Variables Low AFB (n= 9) High AFB (n=8) P value 
Demographics 
   Age (years) 
   Male, (%) 
   BMI (m2/kg)    
   SBP (mmHg) 
 
73.1 ± 9.5 
7, (78) 
24.5 ± 3.8 
139.4 ± 15.4 
 
78.0 ± 7.7 
6, (75) 
31.0 ± 2.8 
147.4 ± 18.9 
 
0.26 
0.90 
0.01 
0.36 
Co-morbidities 
   Hypertension, (%) 
   Ischaemic heart disease, (%) 
   Antiplatelet, (%) 
 
7, (78) 
2, (22) 
7, (78) 
 
7, (88) 
2, (25) 
6, (75) 
 
 
Cumulative % pacing 
   Atrial pacing, % 
   Ventricular pacing, % 
 
52.0 (8.7 – 79.0)  
99.0 (41.0 – 99.9) 
 
18.2 (5.0 – 34.0)  
98.5 (21.1 – 99.9 ) 
 
0.28 
0.97 
Left Atrial (LA) Remodelling 
   LA Dimension, cm 
   LA Volume (AL), ml 
   Index AL, ml/m2 
   Septal A’, cm/s 
 
3.8 ± 0.8 
60.6 ± 16.4 
34.8 ± 9.2 
9.4 ± 1.6 
 
4.4 ± 0.2 
68.5 ± 16.1 
34.9 ± 10.3 
6.2 ± 2.4 
 
0.06 
0.37 
0.98 
0.01 
Left Ventricle Systolic 
   Ejection Fraction (Simpson), % 
   Septal S, cm/s 
 
58.0 ± 11.3 
6.9 ± 1.6 
 
52.3 ± 5.9 
6.0 ± 0.9 
 
0.23 
0.19 
Left Ventricle Diastolic 
   E/A 
   IVRT, ms 
   Septal E’, cm/s  
   Septal E/E’  
 
0.8 (0.6 – 0.8) 
108.9 ± 15.4  
5.5 ± 1.5 
14.1 ± 4.0 
 
0.8 (0.8 – 2.0) 
107.5 ± 19.8 
5.8 ± 0.9 
14.1 ± 3.1 
 
0.14 
0.88 
0.59 
0.99 
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Matrix Turnover Markers 
   MMP 1 (ng/ml) 
   TIMP 1 (ng/ml) 
 
1.2 (0.8 – 1.7) 
1.8 (1.5 – 2.3) 
 
1.5 (1.2 – 3.8) 
1.7 (1.1 – 1.9) 
 
0.22 
0.37 
Thrombogenesis markers 
   vWf, IU/dl 
   TF, ng/ml 
   P-sel, ng/ml 
   DDM, ng/ml 
 
91.4 ± 40.4 
0.1 (0.1 – 0.2)  
51.7 ± 12.5 
145.0 (88.0 – 290.0) 
 
96.5 ± 28.0 
0.1 (0.1 – 0.4)  
75.1 ± 37.7 
160.0 (66.0 – 360.0) 
 
0.77 
0.69 
0.13 
0.37 
 
BMI=body mass index; SBP=systolic blood pressure; AL=area-length method; 
IVRT=interventricular relaxation time; MMP 1= Matrix Metalloproteinase 1; TIMP 
1= Tissue Inhibitors of Metalloproteinase -1; vWf= Von Willebrand Factor; TF=Tissue 
Factor; P-sel=P selectin; DDM=D Dimer 
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Table 3.2c Changes in demographic, echocardiographic, pacing and biomarker 
parameters 
Variables Baseline (n=101) Follow up (n-90) p value 
Demographics 
   Height, cm 
   Weight, kg 
   BMI,  kg/m2 
   BSA 
   HR (per min) 
   SBP, mmHg 
   DBP, mmHg 
 
168.94 ± 9.08 
76.30 ± 16.10 
26.58 ± 4.32 
1.89 ± 0.23 
73.16 ± 9.27 
138.2 ± 22.4 
77.2 ± 11.0 
 
168.71 ± 9.79 
75.00 ± 17.90 
26.18 ± 5.08 
1.87 ± 0.25  
69.19 ±  8.03  
136.0 ± 21.6 
74.5 ± 11.5 
 
0.87 
0.61 
0.56 
0.57 
0.01 
0.50 
0.09 
Left Atrial (LA) Remodelling 
   LA Dimension, cm 
   LA Volume (AL), ml 
   Index AL, ml/m2 
   Septal A’, cm/s 
   Lateral A’, cm/s 
 
4.06 ± 0.70 
55.5 ± 16.1 
29.8 ± 9.4 
8.4 ± 2.4 
9.9 ± 3.1 
 
3.93 ± 0.83 
60.9 ± 20.2 
32.6 ± 10.3 
7.6 ±2.4 
8.6 ± 2.9 
 
0.27 
0.06 
0.06 
0.02 
0.01 
Left Ventricle (LV) Measurements  
   Ejection Fraction (Simpson), % 
   Early inflow peak velocity (E), cm/s 
   Late inflow peak velocity (A), cm/s 
   E/A 
   IVRT, ms 
   Septal E’, cm/s  
   Septal E/E’  
   MAPSE, cm 
   Septal S, cm/s 
 
52.6 ± 12.2 
69.0 ± 20.9 
85.1 ± 22.8 
0.77 (0.64 – 0.87)  
108.0 ± 20.8 
5.29 ± 1.63 
14.14 ± 6.34 
1.46 ± 0.33 
6.46 ± 1.69 
 
49.5 ± 10.5 
72.1 ± 23.9 
78.9 ± 23.1 
0.83 (0.65 – 1.20)  
117.4 ± 28.2 
5.15 ± 1.66 
15.56 ± 8.26 
1.41 ± 0.33 
6.13 ±1.79 
 
0.07 
0.34 
0.07 
0.02 
0.01 
0.56 
0.19 
0.25 
0.20 
Right Ventricle Measurement 
   TAPSE, cm 
 
2.31 ± 0.53 
 
2.07 ± 0.58 
 
0.01 
Pacing Percentage 
Atrial pacing (%) 
   Ventricular pacing (%) 
 
34.6 (6.5 – 85.8) 
41.0 (3.9 – 99.5) 
 
45.8 (6.9 – 83.5) 
69.7 (2.0 – 100.0) 
 
0.77 
0.52 
Matrix Turnover Markers 
   MMP 1 (ng/ml) 
   TIMP 1 (ng/ml) 
 
1.30 (0.78 – 2.60) 
1.50 (1.20 – 1.90) 
 
0.35 (0.20 – 0.62) 
4.20 (3.24 – 5.75) 
 
0.00 
0.00 
Thrombogenesis markers 
   TF, ng/ml 
   P-sel, ng/ml 
   DDM, ng/ml 
 
0.14 (0.09 – 0.32)  
50.2 ± 19.6 
195.0 (89.0 – 
375.0) 
 
0.15 (0.10 – 0.32)  
85.8 ± 30.3 
420.0 (290.0 – 
680.0) 
 
0.59 
0.00 
0.01 
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BMI=body mass index; BSA=body surface area; HR=heart rate; SBP=systolic blood 
pressure; DBP=diastolic blood pressure; AL=area-length method; E/A=ratio between 
early and late inflow peak velocity; IVRT=interventricular relaxation time; E’=peak 
early myocardial velocity; A’=late myocardial velocity; S= myocardial systolic wave; 
E/E’=ratio between early inflow peak velocity with peak early myocardial velocity; 
MAPSE= mitral annular plane of systolic excursion; TAPSE=tricuspid annular plane 
of systolic excursion; MMP 1= Matrix Metalloproteinase 1; TIMP 1= Tissue Inhibitors 
of Metalloproteinase -1;TF=Tissue Factor; P-sel=P selectin; DDM=D Dimer 
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Table 3.2d Sub-group analysis of patients with AHRE (n=35) 
Variables Baseline  Follow up  p value 
Demographics 
   Height, cm 
   Weight, kg 
   BMI,  kg/m2 
   BSA 
   HR (per min) 
   SBP, mmHg 
   DBP, mmHg 
 
168.53 ± 7.17 
75.40 ± 12.70 
26.53 ± 4.08 
1.87 ± 0.18 
73.74 ± 8.83 
138.8 ± 19.3 
77.3 ± 10.4 
 
170.7 ± 8.23 
72.10 ± 12.90 
24.84 ± 4.32 
1.84 ± 0.18  
70.61 ±  8.36  
135.7 ± 19.7 
77.0 ± 11.8 
 
0.25 
0.30 
0.10 
0.49 
0.14 
0.52 
0.92 
Left Atrial (LA) Remodelling 
   LA Dimension, cm 
   LA Volume (AL), ml 
   Index AL, ml/m2 
   Septal A’, cm/s 
   Lateral A’, cm/s 
 
4.12 ± 0.62 
61.2 ± 19.6 
33.2 ± 10.1 
8.1 ± 2.7 
9.5 ± 3.7 
 
4.06 ± 0.79 
70.3 ± 19.1 
37.9 ± 8.4 
6.9 ±2.1 
8.1 ± 3.2 
 
0.74 
0.01 
0.01 
0.03 
0.14 
Left Ventricle (LV) Measurements  
   Ejection Fraction (Simpson), % 
   Early inflow peak velocity (E), cm/s 
   Late inflow peak velocity (A), cm/s 
   E/A 
   IVRT, ms 
   Septal E’, cm/s  
   Septal E/E’  
   MAPSE, cm 
   Septal S, cm/s 
 
52.7 ± 12.5 
69.4 ± 22.4 
81.2 ± 28.2 
0.79 (0.66 – 0.86)  
108.6 ± 19.6 
5.47 ± 1.77 
13.6 ± 6.22 
1.49 ± 0.35 
6.45 ± 1.56 
 
50.8 ± 10.4 
75.3 ± 19.4 
74.9 ± 25.2 
0.90 (0.78 – 1.40)  
112.7 ± 24.9 
5.26 ± 1.84 
16.4 ± 9.14 
1.38 ± 0.33 
5.69 ±1.58 
 
0.51 
0.04 
0.34 
0.02 
0.45 
0.56 
0.07 
0.06 
0.01 
Right Ventricle Measurement 
   TAPSE, cm 
 
2.20 ± 0.46 
 
1.97 ± 0.58 
 
0.04 
Pacing Percentage 
Atrial pacing (%) 
   Ventricular pacing (%) 
   AF burden (%) 
   PAC/hr 
 
52.0 (4.9 – 94.8) 
59.0 (11.0 – 99.8) 
0.3 (0.0 – 5.9) 
0.3 (0.0 – 42.6) 
 
65.0 (3.6 – 91.0) 
89.0 (12.3 – 100.0) 
2.6 (0.1 – 26.4) 
6.8 (0.3 – 168.9) 
 
0.56 
0.09 
0.33 
0.23 
Matrix Turnover Markers 
   MMP 1 (ng/ml) 
   TIMP 1 (ng/ml) 
 
1.55 (1.15 – 3.48) 
1.16 (1.13 – 1.85) 
 
0.37 (0.23 – 0.57) 
4.45 (3.53 – 6.25) 
 
0.00 
0.00 
Thrombogenesis markers 
   TF, ng/ml 
   P-sel, ng/ml 
   DDM, ng/ml 
 
0.12 (0.09 – 0.21)  
54.9 ± 24.8 
187.5 (133.8 – 303.8) 
 
0.13 (0.09 – 0.20)  
87.7 ± 32.5 
440.0 (280.0 – 680.0) 
 
0.22 
0.00 
0.00 
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BMI=body mass index; BSA=body surface area; HR=heart rate; SBP=systolic blood 
pressure; DBP=diastolic blood pressure; AL=area-length method; E/A=ratio between 
early and late inflow peak velocity; IVRT=interventricular relaxation time; E’=peak 
early myocardial velocity; A’=late myocardial velocity; S= myocardial systolic wave; 
E/E’=ratio between early inflow peak velocity with peak early myocardial velocity; 
MAPSE= mitral annular plane of systolic excursion; TAPSE=tricuspid annular plane 
of systolic excursion; MMP 1= Matrix Metalloproteinase 1; TIMP 1= Tissue Inhibitors 
of Metalloproteinase -1;TF=Tissue Factor; P-sel=P selectin; DDM=D Dimer 
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Table 3.2e Correlation of percentage AF burden with echocardiography 
parameters and percentage pacing 
 Ind AL E/A TAPSE MAPSE Sep A’ Sep S %AP %VP 
AF burden     
r 
p 
 
0.505 
0.003 
 
0.545 
0.002 
 
-0.362 
0.054 
 
-0.319 
0.070 
 
-0.548 
0.001 
 
-0.422 
0.014 
 
-0.297 
0.093 
 
0.298 
0.092 
 
AF=atrial fibrillation; Ind AL=indexed area-length; E/A=ratio between early and late 
inflow peak velocity; MAPSE= mitral annular plane of systolic excursion; 
TAPSE=tricuspid annular plane of systolic excursion; Sep A= A’=late myocardial 
velocity; Sep S= myocardial systolic wave; %AP=percentage atrial pacing; 
%VP=percentage ventricular pacing 
 
 
 
 
 
Table 3.2f Correlation of LA volume with echocardiography parameters, AF 
burden and biomarkers 
 E/A Sep A’ Sep S %AP %VP AF 
burden 
TIMP 1 
Indexed LA     
r 
p 
 
0.420 
0.019 
 
-0.667 
0.000 
 
-0.539 
0.001 
 
0.024 
0.893 
 
0.249 
0.163 
 
0.505 
0.003 
 
0.648 
0.000 
 
AF=atrial fibrillation; Ind AL=indexed area-length; E/A=ratio between early and late 
inflow peak velocity; Sep A= A’=late myocardial velocity; Sep S= myocardial systolic 
wave; %AP=percentage atrial pacing; %VP=percentage ventricular pacing, TIMP1= 
Tissue Inhibitors of Metalloproteinase -1 
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3.3.1 INTERATRIAL CONDUCTION TIME IN PATIENTS WITH 
PACEMAKER: DEVELOPMENT OF A NEW METHOD OF ASSESSMENT 
 
Interatrial conduction time (IACT) plays an important role in the mechanisms of atrial 
fibrillation [Platonov 2007]. Prolonged interatrial conduction time is a major 
predisposing factor for the development of atrial tachy-arrhythmias [Leier et al. 1978]. 
Traditionally, P-wave morphology, P-wave dispersion, P-wave duration and P-wave 
signal-averaging techniques have been used as non-invasive techniques for assessment 
of atrial conduction [Agarwal et al. 2003, Stafford et al. 1991, Steinberg et al. 1993]. 
Activation of the atria can also be measured by tissue Doppler imaging (TDI) [Di Salvo 
et al. 2005, Lind et al. 2002, Sutherland et al. 1999, Thomas et al. 2003, Topsakal et al. 
2004]. The transthoracic TDI measurement of total atrial conduction time (TACT) has 
been demonstrated to be a simple, fast and reliable method to estimate TACT and was 
an independent predictor of new onset of AF in general population [De Vos et al. 
2009]. 
 
Limitations of current non-invasive methods  
Previous non-invasive methods of assessing IACT had major limitations. The initiation 
of P wave on ECG is not always evident. Hence the measurement of P-wave duration is 
highly variable. The use of P-SAECG has improved the accuracy of measuring P-wave 
duration. However, the data on reproducibility filter settings, total number of beats to 
be averaged, the small amplitude of atrial ECG and the offset of P-wave all depends on 
the different system used.  
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The methods of obtaining P-wave dispersion also varies. Some studies used digital 
signal-averaging system, others measured P wave dispersion manually on paper or high 
resolution computer screen from 12 or 16 ECG leads were used [Aytemir et al. 
2000,Ciaroni et al. 2000, Dilaveris et al. 1998, 1999a, 1999b, 2000, Fan et al. 2000, 
Gilligan et al. 2000, Weber et al. 1998]. Dilaveris and colleagues have reported a poor 
agreement between the manual on screen versus digitally measured P-wave dispersion, 
and the mean intra- and inter-observer variability can be as high as 20% [Dilaveris et al. 
1999]. This has posed a question on reliability, accuracy and reproducibility on the 
methods of measuring P-wave dispersion.   
 
The TDI method relies heavily on the electrocardiographic P wave recorded by the 
echocardiographic machine, of which could be variable in nature. There may also be a 
minor delay in ECG processing on echocardiography machine. It also fails to address 
the issue of variability of the initiation of atrial contraction (P-wave) and the variable 
heart rate. The impact of variable heart rate and loading conditions on the TDI interval 
will also require further study. 
 
Therefore, these measures of IACT suffer from the following limitations: 
1. Difficulties in P wave measurement and reproducibility 
2. Failure to adjust for heart rate 
 
Novel Measurement of IACT 
The proposed novel interatrial conduction time (IACT) was defined as the time interval 
between the activation of atrial electrical event to mechanical event. This measure, 
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which includes the electrical conduction time and the electromechanical delay, 
therefore, represents a global measure of interatrial electromechanical activation. 
 
This proposed technique will employ atrial pacing at a specified rate in order to 
overcome the limitations associated with difficulties in measuring P wave onset and 
variable atrial rates. This calculation was done by using two separate measurements: (i) 
the time from atrial pacing to the start of the QRS (Ap-QRS) via the pacemaker 
programmer (electrical event), (ii) the time from peak A' to the start of the QRS (A’-
QRS) on tissue Doppler echocardiography parameter (mechanical event), the sample 
volume was placed on the septal wall of the left atrium just above the mitral annulus in 
the apical 4-chamber view. The IACT was the difference between Ap-QRS time and 
peak A'-QRS time [Figure 3.3a]. Although the pacemaker programmer improves the 
accuracy of the measurements, it is not easy to separate the interval into electrical and 
mechanical event. Instead, this IACT measures overall electromechanical atrial 
activation. This calculation was performed when patients were paced at constant rate of 
80, 100, 120 beats per minute for at least 3 minutes prior to measurements and 
averaging of 3 cardiac cycles.  
 
 Intra and inter-observer variability 
Reproducibility of the above technique was performed by 2 observers on 5 separate 
visits. There was good agreement between observers. Both intra and inter-observer 
variability were <5% [Figure 3.3b, 3.3c]. 
 
Limitations of IACT measurement    
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The proposed method of IACT measurement does have limitations. First of all, it can 
only apply on patients with pacemakers as it requires atrial pacing. However, 
measuring IACT during atrial pacing allow us to control for heart rate variability. 
Furthermore, the atrial activation will be abnormal in pacemaker patient. The atrial 
activation starts from right atrial appendage (or where atria lead is) rather than sinus 
node, but at least this is standardised within the same patient and between patients. 
There is also a potential latency associated with pacing stimulation, but this is usually 
small. 
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Interatrial conduction time = A – B  
Figure 3.3a Illustration of measurement of interatrial conduction time 
 
 
 
Figure 3.3b Intra-observer variability of IACT measurement 
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Figure 3.3c Inter-observer variability of IACT measurement 
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3.3.2 MEASUREMENT OF INTERATRIAL CONDUCTION TIME AND 
RELATIONSHIPS WITH ATRIAL HIGH RATE EPISODES IN PATIENTS 
WITH DUAL CHAMBER PACEMAKERS 
 
ABSTRACT 
Background: Delayed interatrial conduction time (IACT) is associated with atrial 
fibrillation (AF). However, the IACT measurement has limitations - the start of the P 
wave is often unclear and the effect of variable atrial rate is not accounted for.  In this 
study, we tested a novel method of assessing IACT and the relationship with atrial high 
rate episodes (AHRE) in pacemaker population.  
Method: We measured IACT in 70 patients with dual chamber pacemakers (atrial lead 
in the right atrial appendage). IACT was measured by: (i) atrial pacing (Ap) at 80, 100 
and 120bpm, (ii) measuring the time from Ap to the start of the QRS (Ap-QRS) via the 
pacemaker programmer, (iii) measuring the time from peak A' to the start of the 
QRS(A’-QRS) on tissue Doppler echocardiography parameter. The IACT was the 
difference between Ap-QRS time and peak A'-QRS time. Left atrial volume (LAV) was 
measured by the ellipsoid method and global LA function by Septal A’.AHRE and AF 
burden were derived from pacemaker diagnostics.  
Results: Inter- and intra-observer variability for IACT measurementswere3.5% and 
2.6% respectively. Eighteen patients had AHRE. Demographics and co-morbidities 
were similar between groups. IACT increased from 80 to 120bpm in both groups. 
Patients with AHRE had significantly higher Vp [p=0.049] and change in IACT from 
80-120bpm (∆IACT) [p=0.042].Changes in LAV and Septal A’ were not statistically 
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significant. IACT 100 [r=0.347, p=0.003], IACT 120 [r=0.321, p=0.008] and ∆IACT 
[r=0.281, p=0.02] were all negatively correlated with Septal A’ 
Conclusion: This method of IACT measurement in patients with permanent 
pacemakers is feasible and reproducible. ∆IACT was more pronounce in patient with 
AHRE. However, prolongation of IACT at higher pacing rate was associated with 
increased LA volume, reduced global LA function and LV function. 
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INTRODUCTION 
 
Cardiac pacing is an effective treatment for bradyarrhythmias supported by 
international guidelines [Epstein et al. 2008, Vardas et al. 2007]. The development of 
AF in pacemaker population has been reported by numerous studies and the incidence 
is higher in patients with single chamber ventricular (VVI) pacing systems when 
compared to dual chamber or atrial pacing systems. RV apical pacing either as single 
chamber (VVI mode) or dual chambers (DDD mode) may have detrimental effects on 
cardiac structure and function [Sweeney and Prinzen 2006]. 
 
Contemporary pacemaker and other implantable cardiac rhythm devices that 
incorporate an atrial lead allow the storage of atrial high-rate episodes (AHRE), and 
potentially detailed characterisation of atrial fibrillation (AF) recurrences. Pollak et al. 
showed that the detection of AHRE correlates well with ECG documentation of AF, 
especially if higher atrial rates of >250 beats/min and episodes of longer duration (>5 
minutes) are used [Pollak et al. 2001]. AF burden as defined by pacemaker device does 
vary depending on pacemaker setting. In clinical practice, AF burden is usually 
expressed as percentage of time spends in AHRE over a day period. Thus, device-
detected AHREs, when appropriately defined may be reliable estimates of AF episodes. 
 
Interatrial conduction time (IACT) plays an important role in the mechanisms of atrial 
fibrillation [Platonov 2007]. Prolonged interatrial conduction time is a major 
predisposing factor for the development of atrial tachy-arrhythmias [Leier et al. 1978]. 
Traditionally, P-wave morphology and P-wave signal-averaging techniques have been 
used as non-invasive techniques for assessment of atrial conduction [Agarwal et al. 
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2003, Stafford et al. 1991, Steinberg et al. 1993]. Activation of the atria can also be 
measured by tissue Doppler imaging (TDI) [Di Salvo et al. 2005, Lind et al. 2002, 
Sutherland et al. 1999, Thomas et al. 2003, Topsakal et al. 2004]. 
 
One novel technique measures total atrial conduction time (TACT) using transthoracic 
TDI of the atrial has been validated against P-wave duration on signal-averaged 
electrocardiography [Merckx et al. 2005]. This new non-invasive method (the time 
interval from the initiation of the P wave on electrocardiography to the peak A’ wave of 
the atrial tissue Doppler tracing) has been demonstrated to be a simple, fast and reliable 
method to estimate TACT and was an independent predictor of new onset of AF in 
general population [De Vos et al. 2009]. However, this method relies on identifying the 
onset of the P wave on the electrocardiographic recording on the echocardiographic 
machines, which are typically limited to 3 ECG leads and the onset of the P wave 
difficult to discern. 
 
In contrast, the onset of atrial activation can be clearly defined when delivered by atrial 
pacing. This was the basis for the novel measure of IACT described in previous 
chapter. This novel measure of IACT measurement is feasible and reproducible. 
 
The present study aims to evaluate (i) the effect of atrial rate on interatrial conduction 
time; and (ii) and the relationship between this measure of IACT with AHRE. 
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METHODS 
 
The study populations, pacemaker interrogation, echocardiographic as well as statistical 
analysis have been described in detail in Chapter 2. The proposed novel method of 
interatrial conduction time measurement has been described in previous chapter. 
 
RESULTS 
 
Seventy patients with dual chamber pacemakers were included in this study. The mean 
age was 73.1 ± 10.8 years, and most patients were men (66%). Eighteen patients had 
AHREs as defined as atrial-rate ≥ 220 beats/min for ≥ 5 minutes. Patients were divided 
according to the presence or absence of AHREs. Baseline characteristics and co-
morbidities were comparable between groups [Table 3.3a].  
 
Patients with AHREs had significantly higher cumulative ventricular pacing (p=0.049) 
and atrial pacing (p=0.061). Left ventricular systolic and diastolic parameters were 
comparable between groups. There was a trend towards larger LA volume and reduced 
global function in patients with AHRE but this did not reach statistical significant 
[Table 3.3b]. 
 
IACT was measured at 3 different atrial pacing rates (80, 100 and 120/minute). IACT 
increased from pacing rate of 80 to 120 beats/min in both groups [Figure 3.3d]. The 
change in IACT (∆IACT) between 80 and 120 beats/min was significantly longer in 
patients with AHRE (p=0.042).  
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IACT at 80, 100 and 120/min had a weak but significant correlation with cumulative 
percentage atrial pacing [r=0.240, r=0.287, r=0.295; respectively (all p<0.05)]. ∆IACT 
had significant correlation with indexed LAV [r=0.320, p=0.012], diastolic parameter 
of septal E/E’ [r=0.268, p=0.027] and was negatively correlated with Septal A’ 
[r=0.281, p=0.02]. The ∆IACT were also inversely correlated with Septal S at 80 
beats/min (r=0.380, p=0.001), Septal S at 100 beats/min (r=0.466, p<0.001) and Septal 
S at 120 beats/min (r=0.495, p<0.001). Inter- and intra-observer variability showed 
good agreement in measurement of IACT (3.5% and 2.6% respectively). 
 
35 patients had repeat measurement of IACT and echocardiogram performed during 
their follow-up with the median of 316.0 (IQR 293.0 – 361.0) days, and most patients 
were men (60%). Compare to baseline study, patients at follow up visit had significant 
better blood pressure control (p=0.035), larger LA volume (p=0.003) along with 
reduced LV ejection fraction (p=0.04) [Table 3.3c]. However, the global LA function, 
cumulative atrial and ventricular pacing showed no statistically different. The ∆IACT 
between 80 and 120 beats/min was significantly longer during follow up (p=0.039).  
 
During follow up study, indexed LA volume correlated with baseline LA volume 
(r=0.654, p<0.001), percentage VP (r=0.375, p=0.029) and negatively correlated with 
global septal A’ (r=0.437, p=0.010) and septal S (r=0.466, p=0.006). Regression 
analysis demonstrated that baseline LA volume and septal S (both p<0.05) were 
strongly predictive of indexed LA volume during follow up. The ∆IACT between 80 
and 120 beats/min also correlated with baseline indexed LA volume (r=0.417, 
p=0.020), baseline ∆IACT (r=0.554, p=0.001) and negatively correlated with global 
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septal A’ (r=0.492, p=0.005) as well as septal S (r=0.408, p=0.015). Only baseline 
∆IACT (OR 2.94, p=0.007) and septal A’ (OR 2.09, p=0.047) remained strongly 
predictive of ∆IACT during follow up.  
 
DISCUSSION 
 
In this study, I describe a method of IACT measurement in patients with permanent 
pacemakers which is feasible and reproducible. In addition, ∆IACT was more 
pronounce in patient with AHRE. However, prolongation of IACT at higher pacing rate 
was associated with increased LA volume, reduced global LA function and LV 
function. 
 
Intra-atrial conduction time has been shown in numerous studies as independent 
predictors of AF development [De Vos et al. 2009, Duytschaever et al. 2006, Roshanali 
et al. 2007]. De Vos et al. demonstrated that the longer the interval, the higher the 
incidence of new onset AF in the general population. The novel measurement of IACT 
in my study were formulated with define atrial electrical activation (right atrial 
appendage) and at fix pacing rates in patients with dual chamber pacemaker [De Vos et 
al. 2009]. Previous studies had demonstrated that RA appendage pacing worsen the 
interatrial conduction delay by increasing the interatrial conduction time which was 
evident on intracardiac electrogram [Hermida et al. 2004, De Voogt et al. 2003]. 
Although the novel measurement I proposed had a significant correlation with 
percentage of atrial pacing, it did not predict the development of AHREs. This implies 
that there is probably not a direct relationship between IACT and development of AF. 
Indeed, a multicentre study by Padeletti and colleague had also shown that pacing at 
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difference RA site with different interatrial conduction time was not superior to RA 
appendage pacing [Padeletti et al. 2003]. The study of IACT at higher pacing rate 
(120bpm) does mimicking low level of exercise. Indeed, it was the difference of IACT 
at high (120bpm) and low rate (80bpm) atrial pacing that predicted the development of 
AHREs. This suggests patients with intermittent tachycardia are more likely to induce 
interatrial conduction abnormality in turn give rise to the development of AF.  
 
In this study, I demonstrated the prolongation of IACT had significant correlations with 
increase LA volume, reduce global LA function and LV systolic function. The atria are 
not just a passive conduit for blood but also contribute actively to ventricular filling. 
This reduced in LA function has influenced on the conduit, reservoir and active 
pumping phase of LA function which in turns reduce the LV diastolic function (LV 
filling) and subsequently affect LV systolic function. The small study on follow up also 
demonstrated that as LA volume increased, LV systolic function reduced without 
significant changes on global LA function. The changed in IACT was more prominent 
at follow up and this prolongation is highly predictive by baseline LA function and 
IACT. This suggests the structural (LAV), electrical (IACT) and functional remodelling 
of LA are closely related to each other. 
 
This IACT measurement was measured during atrial pacing which is the main 
limitation of this measurement as atrial pacing is not a representative of normal atrial 
conduction via sinus node activation. Besides, latency from atrial pacing may also 
contribute to IACT measurement. This is a relatively small study and this concept of 
new measurement needs further evaluation.  
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CONCLUSION 
In our study, I demonstrated that a novel method of IACT measurement in patients with 
permanent pacemakers is feasible and reproducible. IACT changes were more 
pronounced in patient with documented AHRE, and IACT prolongation at higher 
pacing rate was also associated with increase LA volume, reduced global LA and LV 
function. Further studies validating this approach would gauge its clinical utility. 
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Figure 3.3d Line plot of interatrial conduction time at various pacing rate 
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Table 3.3a Clinical characteristics of IACT groups 
Variables No AHRE (n= 52) AHRE (n=18) P value 
Demographics 
   Age, years 
   Male, (%) 
   Height, cm 
   Weight, kg 
   BMI, m2/kg 
   HR, beats/min 
   SBP, mmHg 
   DBP. mmHg 
 
72.0 ± 11.8 
36, (69) 
168.8 ± 9.6 
74.0 ± 15.6 
25.8 ± 3.6 
71.2 ± 8.7 
139.2± 23.3 
76.1 ± 11.5 
 
75.7 ± 8.3 
10, (56) 
168.1 ± 7.5 
78.6 ± 12.4 
27.9 ± 4.4 
73.7 ± 10.8 
146.6± 20.3 
78.4 ± 12.6 
 
0.16 
0.33 
0.75 
0.21 
0.08 
0.39 
0.21 
0.49 
Co-morbidities 
   Hypertension, (%) 
   Diabetes, (%) 
   Ischaemic heart disease, (%) 
   Stroke / TIA, (%) 
   Hypercholesterolaemia, (%) 
   Antiplatelet, (%) 
   ACEi / ARB, (%) 
   Beta-blocker, (%) 
   Diuretics, (%) 
   Statin, (%) 
 
34, (65) 
8, (15) 
22, (42) 
6, (12) 
35, (67) 
37, (71) 
32, (62) 
18, (35) 
19, (37) 
35, (67) 
 
13, (72) 
4, (22) 
5, (28) 
1, (5) 
15, (83)  
10, (56) 
11, (61) 
4, (22) 
7, (39) 
10, (56) 
 
0.60 
0.55 
0.27 
0.41 
0.16 
0.26 
0.98 
0.31 
0.86 
0.40 
Cumulative % pacing 
   Atrial pacing, % 
   Ventricular pacing, % 
 
31.1 (6.9 – 78.1)  
10.7 (1.0 – 99.7) 
 
91.0 (20.2 – 95.3)  
90.4 (17.0 – 100.0 ) 
 
0.06 
0.05 
 
BMI=body mass index; HR=heart rate; SBP=systolic blood pressure; DBP=diastolic 
blood pressure; ACEi=angiotensin converting enzyme inhibitor; ARB=angiotensin 
receptor blocker 
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Table 3.3b Standard echocardiographic measurements and interatrial conduction 
time 
Variables No AHRE (n= 52) AHRE (n=18) P value 
Left Atrial (LA) Remodelling 
   LA Dimension, cm 
   LA Volume (AL), ml 
   Indexed LAV, ml/ 
   Septal A’, cm/s 
 
4.0 ± 0.8 
51.3 ± 15.7 
28.1 ± 8.6 
8.7 ± 2.0 
 
4.1 ± 0.7 
57.8 ± 13.3 
30.5 ± 7.6 
7.6 ± 2.2 
 
0.69 
0.10 
0.28 
0.08 
Left Ventricle (LV) Function 
   Ejection Fraction (Simpson), % 
   Septal S, cm/s 
   Lateral S, cm/s 
   E, cm/s 
   A, cm/s    
   E/A 
   IVRT, ms    
   DT, ms 
   Septal E’, cm/s  
   Septal E/E’ 
 
53.4 ± 12.5 
6.4 ± 1.7 
8.3 ± 2.4 
67.0 ± 22.3 
86.9 ± 20.3 
0.8 ± 0.3 
107.3 ± 23.3 
255.6 ± 74.2 
5.1 ± 1.8 
14.4 ± 6.9 
 
55.5 ± 11.1 
6.2 ± 1.1 
7.5 ± 1.8 
72.4 ± 20.6 
91.5 ± 24.9 
0.8 ± 0.3 
107.2 ± 18.4 
259.4 ± 63.0 
5.2 ± 1.4 
14.1 ± 3.5 
 
0.52 
0.53 
0.20 
0.35 
0.48 
0.73 
0.99 
0.83 
0.96 
0.85 
 Right Ventricle function 
   TAPSE, mm 
 
22.7 ± 6.8 
 
22.2 ± 6.0 
 
0.78 
Inter-atrial Conduction Time 
   IACT 80 
   IACT 100 
   IACT 120 
   Δ IACT  
 
160.0 (145.0 – 190.0) 
180.0 (156.3 – 210.0) 
200.0 (183.8 – 230.0) 
40.0 (20.0 – 62.5) 
 
170.0 (147.5 – 190.0) 
190.0 (170.0 – 205.0) 
220.0 (197.5 – 252.5) 
50.0 (37.5 – 77.5) 
 
0.81 
0.37 
0.17 
0.04 
Systolic function at various pacing 
   S 80, cm/s 
   S 100, cm/s 
   S 120, cm/s 
 
6.8 ± 2.0 
7.1 ± 2.6 
7.3 ± 2.9 
 
6.9 ± 1.5 
7.3 ± 2.2 
7.3 ± 2.0 
 
0.84 
0.74 
0.94 
 
E=early inflow peak velocity; A=late inflow peak velocity; E/A=ratio between early 
and late inflow peak velocity; IVRT=interventricular relaxation time; DT=deceleration 
time; E’=peak early myocardial velocity; A’=late myocardial velocity; S= myocardial 
systolic wave; E/E’=ratio between early inflow peak velocity with peak early 
myocardial velocity; MAPSE= mitral annular plane of systolic excursion; 
TAPSE=tricuspid annular plane of systolic excursion; IACT=interatrial conduction 
time; Δ IACT=changed in interatrial conduction time 
 
 
102 
 
 
Table 3.3c Changes in demographic, echocardiographic, pacing and interatrial 
conduction time 
Variables Baseline Follow up P value 
Patient Characteristics 
   BMI 
   BSA 
   HR 
   SBP 
   % AP 
   % VP 
 
26.9 ± 3.4 
1.9 ± 0.2 
71.1 ± 9.2 
136.9 ± 18.3 
46.0 (14.3 – 88.8) 
56.0 (2.0 – 100.0) 
 
27.0 ± 4.3 
1.8 ± 0.2 
69.7 ± 8.1 
131.7 ± 17.6 
59.0 (20.0 – 87.0) 
66.4 (1.5 – 100.0) 
 
0.83 
0.34 
0.30 
0.04 
0.27 
0.97 
Left Atrial (LA) Remodelling 
   LA Dimension, cm 
   LA Volume (AL), ml 
   Indexed LAV, ml/ 
   Septal A’, cm/s 
   Lateral A’, cm/s 
 
4.1 ± 0.7 
53.0 ± 16.5 
27.7 ± 8.0 
8.6 ± 2.6 
9.8 ± 3.7 
 
4.1 ± 0.8 
62.1 ± 20.5 
32.6 ± 10.5 
8.0 ± 2.4 
9.6 ± 2.6 
 
0.70 
0.01 
0.01 
0.12 
0.79 
Left Ventricle (LV) Function 
   Ejection Fraction (Simpson), % 
   Septal S, cm/s 
   Lateral S, cm/s 
   E, cm/s 
   A, cm/s    
   E/A 
   IVRT, ms    
   DT, ms 
   Septal E’, cm/s  
   Septal E/E’ 
 
53.1 ± 13.1 
6.4 ± 1.7 
7.9 ± 2.2 
69.5 ± 22.6 
85.3 ± 23.5 
0.8 ± 0.3 
104.0 ± 21.9 
256.8 ± 63.2 
5.3 ± 1.8 
13.8 ± 4.3 
 
48.7 ± 9.9 
6.6 ± 2.0 
7.3 ± 2.1 
70.7 ± 24.4 
81.0 ± 23.2 
1.0 ± 0.3 
118.3 ± 27.1 
251.8 ± 61.7 
5.2 ± 1.9 
15.5 ± 9.1 
 
0.04 
0.30 
0.02 
0.67 
0.12 
0.10 
0.02 
0.73 
0.70 
0.22 
 Right Ventricle function 
   TAPSE, mm 
 
22.2 ± 5.5 
 
20.8 ± 5.7 
 
0.12 
Inter-atrial Conduction Time 
   IACT 80 
   IACT 100 
   IACT 120 
   Δ IACT  
 
169.1 ± 42.2 
185.7 ± 47.6 
207.3 ± 51.2 
30.0 (20.0 – 55.0) 
 
162.0 ± 37.3 
180.9 ± 33.1 
213.0 ± 42.6 
40.0 (20.0 – 70.0) 
 
0.27 
0.48 
0.50 
0.04 
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Systolic function at various pacing 
   S 80, cm/s 
   S 100, cm/s 
   S 120, cm/s 
 
7.1 ± 2.1 
7.3 ± 2.8 
7.5 ± 2.9 
 
6.8 ± 1.8 
6.7 ± 2.1 
6.7 ± 2.6 
 
0.17 
0.08 
0.04 
BMI=body mass index; BSA=body surface area; HR=heart rate; SBP=systolic blood 
pressure; AP=atrial pacing; VP=ventricular pacing; E=early inflow peak velocity; 
A=late inflow peak velocity; E/A=ratio between early and late inflow peak velocity; 
IVRT=interventricular relaxation time; DT=deceleration time; E’=peak early 
myocardial velocity; A’=late myocardial velocity; S= myocardial systolic wave; 
E/E’=ratio between early inflow peak velocity with peak early myocardial velocity; 
MAPSE= mitral annular plane of systolic excursion; TAPSE=tricuspid annular plane 
of systolic excursion; IACT=interatrial conduction time; Δ IACT=changed in 
interatrial conduction time 
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CHAPTER 4. CONCLUSIONS 
 
4.1 Summary of findings 
 
The observation of LA enlargement has been shown at other population studies with 
patients of coronary artery disease, hypertension and heart failure [Abhayaratnaet al 
2006, Tsang et al 2002, 2003] and now with patients with dual-chamber pacemaker in 
my study. There was no clear association between percentages of atrial pacing with 
cardiac remodelling. However, increased ventricular pacing is associated with left atrial 
enlargement and reduced left and right ventricles global function. My study suggests 
that ventricular pacing is the main drive for reverse left atrial remodelling. 
 
All the recruited patients were not known to have AF prior to pacemaker implantation. 
The incident of AHRE in the present study was 35%. Indeed, this is a ‘pure’ group of 
patients who had paroxysmal AF which corresponded to pacemaker detected AHRE. In 
this pure group of paroxysmal AF patients, I found that the LA volume were 
significantly larger. Cumulative VP was significantly higher with the presence of 
AHRE. My study demonstrates that patients develop LA enlargement and AHRE even 
before changes in LV function. There was a significant correlation between AFB and 
global LA function, and with LV diastolic parameters. My study suggests that AHRE 
and AFB may have a dissimilar pathophysiological association with LA, LV function 
and remodelling. The biomarkers of P-selectin (platelet activation) and D-dimer 
(thrombosis) were also found to be independently associated with AFB.  
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At 1 year follow up, I demonstrated that: (i) the changes of LA volume was associated 
with percentage cumulative atrial pacing, (ii) global LA function is associated with LV 
longitudinal and diastolic function and a strong predictor of LA volume, and (iii) LV 
diastolic function, global LA function and AF burden are strong predictors of reverse 
LA remodelling in patients experienced AHREs. A novel finding in my study is the 
demonstration of significant reverse LA remodelling (increased LA volume and 
decreased global LA function) and decreased LV and RV longitudinal function in 
patients with AHREs despite similar cumulative atrial and ventricular pacing both at 
baseline and follow up. I also demonstrated a down regulation of MMP1 and up 
regulation of TIMP1 which suggests a pivotal role of the MMP/TIMP system in 
regulating the process of atrial remodelling. Biomarker levels of P-selectin and D-dimer 
also increased significantly between follow up and baseline studies. However, I am not 
able to identify a clear relationship between levels of biomarkers and the presence of 
AF burden. 
 
I describe a method of IACT measurement in patients with permanent pacemakers 
which is feasible and reproducible. The prolongation of IACT at higher pacing rate was 
associated with increased LA volume, reduced global LA function and LV function. 
The changed of IACT (∆IACT) was also found to be more pronounce in patient with 
AHRE. Although the novel measurement I proposed had a significant correlation with 
percentage of atrial pacing, it did not predict the development of AHREs. This implies 
that there is probably not a direct relationship between IACT and development of AF. 
The changes on IACT at different pacing rate suggest patients with intermittent 
tachycardia are more likely to induce interatrial conduction abnormality in turn give 
rise to the development of AF.  
106 
 
 
The small study on follow up also demonstrated that as LA volume increased, LV 
systolic function reduced without significant changes on global LA function. The 
changed in IACT was more prominent at follow up and this prolongation is highly 
predictive by baseline LA function and IACT. This suggests the structural (LAV), 
electrical (IACT) and functional remodelling of LA are closely related to each other. 
 
4.2 Study limitations 
 
This study has several limitations. First, this study is limited by the relatively small 
sample size and the cohort of patients with mixed co-morbidities which may well affect 
the various parameters of cardiac remodelling. However, this reflect a ‘real life’ 
situation when study elderly cohort who often have other co-morbidities. Although my 
result suggests that impairment of longitudinal function of ventricles may precede the 
development of global ventricle dysfunction, future large prospective studies with a 
longitudinal component are warranted to prove this concept. 
 
Second, the follow-up was not complete. The dropout rate of 10% might have 
significantly impact on the data I collected, analysed and subsequently concluded. 
However, this again reflects the difficulty in study elderly cohort in real life situation. 
 
Third, there are currently no reliable method to identify patient who might have 
asymptomatic and silent AF prior to pacemaker implantation and subsequently being 
recruited into my study. I recruited patients with sino-atrial (SA) and/or atrio-
ventricular (AV) nodes disease who had dual chamber pacemakers. Clearly, the cohort 
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with AHRE had high cumulative ventricular pacing which could be a stronger predictor 
compare to IACT. 
 
Finally, as it is a small study and I do not have clinical outcome data, the clinical 
significance of AHREs cannot be determined at this stage.  
 
4.3 Suggestions for future studies 
 
In my study, the clinical significance of AHREs cannot be determined with a 1 year 
follow up and without clinical outcome data. However, 2 population studies over the 
last 5 years have demonstrated the clinical significant of device detected atrial high rate 
episodes [Glotzer et al. 2009, Healey et al. 2012]. Both of these study shown atrial high 
rate episodes were related to clinical outcome of cerebrovascular and thromboembolic 
events. In the TRENDS study, Glotzer et al. demonstrated that AF burden ≥ 5.5 hours 
on any of 30 prior days during pacemaker interrogation appeared to double 
thromboembolic risk (hazard ratio 2.20, [ Glotzer et al. 2009]. The ASSERT study also 
showed the risk of thromboembolic was more than double (hazard ratio 2.50, 95% CI 
1.28-4.89, p=0.008) in patients who had >6 minutes of atrial high rate episodes [Healey 
et al. 2012]. Further studies are needed to understand the relation between device 
implantation, the atrial lead placement on the development of AHREs and reverse LA 
remodelling. The novel measurement of interatrial conduction time is feasible and 
reproducible in my study. However, further studies validating this approach would 
gauge its clinical utility. 
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4.4 Conclusion 
 
This is the first prospective study to look into the relationship of reverse LA 
remodelling in response to atrial high rate episodes and thrombogenesis markers in 
pacemaker population. In my study, I demonstrated that increased ventricular pacing is 
associated with left atrial enlargement and reduced left and right ventricles global 
function. However, there was no clear association between percentages of atrial pacing 
with cardiac remodelling. The cumulative percentage ventricular pacing and increased 
left atrial volume are associated with the development of atrial high rate episodes, but 
atrial fibrillation burden is independently associated with changes in left atrial function, 
left ventricular diastolic function and indices of platelet activation and thrombosis. 
 
I also demonstrated that a novel method of IACT measurement in patients with 
permanent pacemakers is feasible and reproducible. IACT changes were more 
pronounced in patient with documented AHRE, and IACT prolongation at higher 
pacing rate was also associated with increase LA volume, reduced global LA and LV 
function. Further studies validating this approach would gauge its clinical utility. 
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APPENDICES 
 
1. Standard operating procedures for Enzyme Linked Immuno Sorbant 
Assay (ELISA) 
All methods use: 
All suppliers by Sigma, unless otherwise stated. 
Coating buffer 
Add 0.795 g ( = 795 mg) sodium carbonate and 1.465 g ( = 1,465 mg) sodium hydrogen 
carbonate) to 500 ml distilled water. Place on rotary mixer with magnetic stir bar. This 
will make buffer at pH 9.6. Store at 4oC. 
 
Washing buffer (PBS-T) 
Add 5 phosphate buffer saline (PBS) tablets to one litre of water and 0.5 ml Tween. 
Place on rotamixer with stir bar. 
 
Citrate phosphate buffer 
Add 3.65 g citric acid and 4.73 g sodium hydrogen phosphate to 500 ml distilled water, 
pH of 5.3. To 20 ml citrate phosphate buffer add oneotho-phenylene diamine (OPD) 
tablet and 10 μL hydrogen peroxide. 
 
Our lab uses flat bottomed 96 well microtitre plates. The following methods and 
quantities described are for 2 plates. Therefore, will measure approximately 80 samples 
in duplicate with standards. 
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1.i  ELISA for soluble P-selectin      
1. Coat microtitre plates with 100 μl polyclonal anti-human primary capture 
antibody (R&D) in Ph 7 phosphate buffered saline (PBS) free of additive. 
2. Leave at room temperature for 2 hours or overnight in the fridge of 4◦C. 
3. Discard the solution and wash x3 with wash buffer (250 μl/well). 
4. Add 100 μl blocking buffer [1% bovine serum albumin (BSA) in PBS] to 
minimise non-specific binding. 
5. Discard the solution and wash x3 with wash buffer then add 100 μl 1/5 plasma 
(20μl diluted 80 μl PBS-Tween) to each well in duplicate, with standards and blanks in 
the last 2 column of wells and incubate for >90 minutes. 
6. Discard the solution and wash x3 with wash buffer, then add 100 μl secondary 
detection antibody (R&D) conjugated to biotin (made up to 1% BSA/PBS) to each well 
and incubate for >90 minutes. 
7.  Discard the solution and wash x3 with wash buffer. Then, add 100μl of 1/100 
solution of streptavidin-HRP (R&D) in PBS/Tween to each well and incubate for >60 
minutes. 
8. Discard the solution and wash x3 with wash buffer and add 100μl of pooled 
solutions A plus B (hydrogen peroxide and tetramethyl benzidine) is added – blue 
colour develops. 
9. Stop with 100μl/well of acid solution (1 mol/hydrochloride acid). 
10. Read optical densities at 450 nm on a microplate reader. 
11.  A standard curve is constructed on graph paper by plotting the concentrations 
of the P-selectin standards and blanks on the X-axis and the corresponding optical 
density values on Y-axis. From this curve, P-selectin levels of the samples (ng/ml) are 
read off from the optical densities 
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1.ii ELISA for D-dimer         
1. Coat microtitre plate with 100 μl of a dilution of the primary antiserum (100 μl 
in 20ml coating buffer pH 9.6) overnight in the fridge. 
2. Discard the solution and wash x3, and then add 100 μl of plasma in pbs/tween 
in duplicate, with standards and blanks in the last 2 column of wells and standards. 
Incubate for >90 minutes at room temperature. 
3. Discard the solution and wash x3, add 100 μl secondary antiserum – the 
peroxidase-labelled conjugate (50 μl in 20ml PBS), incubate for >120minutes at room 
temperature. 
4. Discard the solution and wash. 
5. Add 100 μl substrate (OPD, hydrogen peroxide, pH 5 citrate buffer). The 
colour develops in 3 to 5 minutes.   
6. Stop with 100 μl of acid solution.  
7. Read optical densities at 492nm on a microplate reader. 
8. A standard curve is constructed on graph paper by plotting the concentrations 
of the D-dimer standards and blanks on the X-axis and the corresponding optical 
density values on Y-axis. From this curve, D-dimer levels of the samples (IU/dL) are 
read off from the optical densities. 
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1.iii ELISA for Tissue Factor (TF)      
  
1. Tissue factor specific antibody (Abcam) has been precoated onto 96-wells 
plate and blocked. 
2. Add 50μl of plasma sample to each well in duplicate, with standards and 
blanks in the last 2 columns of well and incubate for 2 hours at room temperature. 
3. Discard the solution and wash x3 with wash buffer.  
4. Then, add 50 μl Biotinylated TF antibody to each well and incubate at room 
temperature for 2 hours. 
5. Discard the solution and wash x3 with wash buffer.  
6. Then, add 50μl of streptavidin-HRP in PBS/Tween to each well and incubate 
for 30 minutes. 
7. Discard the solution and wash x3 with wash buffer.  
8. Then, add 50μl of Chromogen substrate to each well and incubate for 12 
minutes or till blue colour density develop. 
9. Stop with 50μl/well of acid solution (1 mol/hydrochloride acid) 
10. Read optical densities at 450 nm on a microplate reader 
11.  A standard curve is constructed on graph paper by plotting the concentrations 
of the TF standards and blanks on the X-axis and the corresponding optical density 
values on Y-axis. From this curve, TF levels of the samples (ng/ml) are read off from 
the optical densities. 
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1.iv ELISA for von Willebrand factor (vWf)     
  
1. von Willebrand factor antibody (Abcam) has been precoated onto 96-wells 
plate and blocked. 
2. Add 50 μl of plasma sample to each well in duplicate, with standards and 
blanks in the last 2 columns of well and incubate for 2 hours at room temperature. 
3. Discard the solution and wash x3 with wash buffer.  
4. Then, add 50 μl Biotinylated vWf antibody to each well and incubate at room 
temperature for 2 hours. 
5. Discard the solution and wash x3 with wash buffer.  
6. Then, add 50μl of streptavidin-HRP in PBS/Tween to each well and incubate 
for 30 minutes. 
7. Discard the solution and wash x3 with wash buffer.  
8. Then, add 50μl of Chromogen substrate to each well and incubate for 12 
minutes or till blue colour density develop. 
9. Stop with 50μl/well of acid solution (1 mol/hydrochloride acid) 
10. Read optical densities at 450 nm on a microplate reader 
11.  A standard curve is constructed on graph paper by plotting the concentrations 
of the vWf standards and blanks on the X-axis and the corresponding optical density 
values on Y-axis. From this curve, vWf levels of the samples (ng/ml) are read off from 
the optical densities. 
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1.v  ELISA for Matrix Metalloproteinase-1 (MMP1)   
   
1. Matrix Metalloproteinase-1antibody (Abcam) has been precoated onto 96-
wells plate and blocked. 
2. Add 100 μl of plasma sample to each well in duplicate, with standards and 
blanks in the last 2 columns of well and incubate for 2.5 hours at room temperature or 
overnight at 4°C. 
3. Discard the solution and wash x4 with wash buffer.  
4. Then, add 100 μl Biotinylated MMP1 detection antibody to each well and 
incubate at room temperature for 1 hour. 
5. Discard the solution and wash x4 with wash buffer.  
6. Then, add 100μl of streptavidin-HRP in PBS/Tween to each well and incubate 
for 45 minutes. 
7. Discard the solution and wash x4 with wash buffer.  
8. Then, add 100μl of substrate reagent to each well and incubate for 30 minutes. 
9. Stop with 50μl/well of acid solution (1 mol/hydrochloride acid) 
10. Read optical densities at 450 nm on a microplate reader 
11.  A standard curve is constructed on graph paper by plotting the concentrations 
of the MMP1 standards and blanks on the X-axis and the corresponding optical density 
values on Y-axis. From this curve, MMP1 levels of the samples (ng/ml) are read off 
from the optical densities. 
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1.vi ELISA for Tissue Inhibitors of Metalloproteinases-1 (TIMP1)  
    
1. Tissue Inhibitors of Metalloproteinases-1antibody (Abcam) has been 
precoated onto 96-wells plate and blocked. 
2. Add 100 μl of plasma sample to each well in duplicate, with standards and 
blanks in the last 2 columns of well and incubate for 2.5 hours at room temperature or 
overnight at 4°C. 
3. Discard the solution and wash x4 with wash buffer.  
4. Then, add 100 μl Biotinylated TIMP1 detection antibody to each well and 
incubate at room temperature for 1 hour. 
5. Discard the solution and wash x4 with wash buffer.  
6. Then, add 100μl of streptavidin-HRP in PBS/Tween to each well and incubate 
for 45 minutes. 
7. Discard the solution and wash x4 with wash buffer.  
8. Then, add 100μl of substrate reagent to each well and incubate for 30 minutes. 
9. Stop with 50μl/well of acid solution (1 mol/hydrochloride acid) 
10. Read optical densities at 450 nm on a microplate reader 
11.  A standard curve is constructed on graph paper by plotting the concentrations 
of the TIMP1 standards and blanks on the X-axis and the corresponding optical density 
values on Y-axis. From this curve, TIMP1 levels of the samples (ng/ml) are read off 
from the optical densities. 
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